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Abst rac t 
Pharmacovigilance is an area where associations need to be detected in large (of-
ten sparse) contingency tables, containing counts of drug and adverse drug events. 
The data are collected in spontaneous reporting databases, where voluntary report-
ing is the only source of information. Because of this, problems often arise due to 
the unreliability of the data and especially the baseline information, which in turn 
makes most measures of association unreliable. 
Some of the standard methods in Pharmacovigilance attempt to remedy this 
problem by deriving a smoothed version of some measure of association, while others 
try to ignore this all together. 
In this thesis, we firstly review some of the methods previously used in Phar-
macovigilance, including the odds ratio and more recent methods whereby different 
forms of smoothing are applied to the basic forms of association measures. We 
outline some of problems associated with these methods with some illustrative ex-
amples. 
Secondly we outline a new approach to the problem, which is based on extracting 
structural information from the data. This information can be derived from various 
sources both inherent in the data and external to the data. This is achieved by 
making use of the similarities among drugs and adverse drug events according to 
their profiles. We discuss various distances suitable for measuring these similarities. 
Thirdly we introduce a new algorithm for exploring high-dimensional data sets, 
which we call Peaker. We discuss the various properties of Peaker when used in 
an exploratory sense, in terms of the two facets of pattern detection and pattern 
verification. We introduce tests for the purposes of pattern verification. We illustrate 
Peaker using examples, both simulated and real. 
Finally we apply the new profiling approach and the Peaker algorithm to the 
problem of signal detection in Pharmacovigilance. In this case we apply the methods 
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to real data sets used in the Pharmacovigilance area to illustrate the improvements 
and differences to the older methods. 
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Chapter 1 
Introduction 
1.1 Background and Motivat ion 
If one looks at the packaging of any drug, the one thing that is instantly disconcerting 
is the number of side effects associated with it. Take Aspirin for instance, there is a 
huge hst of potential side effects ranging from the trivial (drowsiness or indigestion) 
to the serious (vomiting and seizures) and it is suspected that deaths can also occur 
as a result of a severe reaction. Whilst drugs can save lives, they can also kill. The 
number of incidents of side effects to drugs is huge. In the United States alone, it 
has been estimated (as of 1998) that the number of instances of death attributed to 
drug side effects is in the region of some 100,000 each year (the estimate is that some 
3 in every 1000 hospital patients die from an adverse reaction). A similar number 
of deaths can be attributed to medical mistakes. The situation can be far worse in 
other countries, especially in many third world countries where drug monitoring is 
backward and moreover the use of illegal drugs can be profligate. Of course, the 
statistic is not as shocking as it initially appears since, in many cases, the patients 
are suffering from serious conditions and need drastic treatments which have known 
serious side effects. But in many cases severe adverse reactions can be caused by 
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innocent looking drugs and in this case it is imperative that the user is aware of 
the associated risks. This should impress upon the reader the magnitude of the 
problem associated with drug safety and the need for a thorough procedure for drug 
monitoring. 
It is generally the case that most drugs have potentially serious side effects, 
especially if taken inappropriately. The importance of adequately detecting these 
side effects cannot be stressed too highly. Moreover, it is just as important (some 
may argue more important) to have enough power in the detection process so that 
the rare side effects (which as a rule tend to be more serious) can also be picked up. 
For the remainder of this chapter, we will discuss the area of safety detection 
which is specifically designed to detect and act upon side effects of drugs. We will 
give the advantages and disadvantages of various methods of detection (we will refer 
to these methods as safety detection or adverse event detection). We will discuss 
some issues and difficulties associated with this area, possible improvements and the 
need for improved methodologies. 
1.2 Shortcomings of Clinical Trials 
The task of detecting side effects initially rests with the pharmaceutical industry. 
They are required to carry out the necessary clinical trials for the evaluation of the 
risks and benefits of a treatment before a drug is permitted to be marketed. Clinical 
trials are split into four parts which are: 
• Phase I - The initial stages of a trial involving a small population (tens of 
people). Subjects are studied extensively, generally in an inpatient clinic and 
phase I trials normally include dose-range studies. 
• Phase II - A larger population is selected (some 100 — 300) to assess the efficacy 
of the treatment. This usually includes a continuation of the phase I trial in 
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a larger population. 
• Phase III - A randomised control trial is designed to further test for the efficacy 
of a treatment, especially in comparison to other alternative treatments. 
• Phase IV - This trial generally involves the post-marketing assessment of a 
drug in the phase III population. 
Phase IV trials are designed for pharmaceutical companies to discover the long 
term risks and benefits of a drug. Large and carefully designed cohort studies can 
be quite effective in picking up the majority of side effects, particularly the majority 
of commonly occurring side effects. However, many issues arise that question the 
effectiveness of such trials, of which the following are a few: 
• The population used in clinical trials tends to be much more limited when 
compared to the wider population at risk. Typically clinical trial populations 
average only a few thousand people which, while effective for the assessment 
of efficacy, can be lacking when the issue of safety is at stake. Moreover 
clinical trials tend to consist of healthier and younger populations whereas 
the real world populations at risk to drugs tend to be the opposite (special 
patient groups such as children and the elderly are generally not represented 
in clinical trials). Additionally, long term effects may not be studied well in 
a cUnical trial. In particular, it is often the case that, due to the restriction 
of a clinical trial population, many serious but rare side effects cannot be 
effectively detected (consider a side effect with an incidence rate of one in a 
million). This leads to the situation that experience about drugs can be very 
limited at the time of marketing and this is verified by the fact that new side 
effects are constantly discovered after marketing. 
• Most pharmaceutical companies tend to place more emphasis on drug efficacy 
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rather than drug safety. Phase IV chnical trials often are barely carried out 
as a mandatory necessity rather than with the aim of genuine risk prevention. 
• In many cases there are various pressures to market a drug as soon as possi-
ble. These can include financial reasons (clinical trials can be very expensive 
to maintain) as well as the simple need to save lives. As such, safety consid-
erations can often take somewhat of a back-seat. 
• It is generally perceived that there is a shroud of secrecy when it comes to drug 
safety in the pharmaceutical industry and often healthcare professionals are 
kept somewhat in the dark concerning many safety issues. This can be specially 
true in certain countries. Moreover, certain companies will try to minimise or 
deny the side effects of their drugs and this can very much complicate matters 
in terms of effective drug usage. 
Given the points mentioned above, it seems clear that other processes are needed 
in complement to the phase IV trials when the issue of drug safety is at stake. In 
particular, it seems very much necessary that a follow-up process to phase IV trials 
is needed to effectively detect the rare and serious side effects. In the next section we 
will describe a process of drug monitoring which has been very effective in picking 
up side effects that clinical trials tend to miss. 
1.3 Pharmacovigi lance and Post Market ing Surveil-
lance 
1.3.1 Introduction 
Pharmacovigilance is a French word, which has been descried by Begaud as 
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"A discipline involving detection, evaluation and prevention of undesirable effects 
of medicine". 
The United Kingdom Medicines and Healthcare products Regulatory Agency 
(MHRA) defines Pharmacovigilance as 
"...the process of a) monitoring medicines as used in everyday practice to iden-
tify previously unrecognised or changes in the patterns of their adverse effects; b) 
assessing the risks and benefits of medicines in order to determine what action, if 
any, is necessary to improve their safe use; c) providing information to users to opti-
mise safe and effective use of medicines and d) monitoring the impact of any action 
taken". 
The World Health Organization (WHO) defines Pharmacovigilance as "the sci-
ence and activities relating to the detection, assessment, understanding and preven-
tion of adverse effects or any other possible drug-related problems...". 
In particular, we are interested in the area of post-marketing surveillance which 
refers to the constant monitoring of adverse drug events (ADEs) that is carried out 
after the marketing of a drug to ensure the safety of the drug in question, both in the 
short term and the long term. Trontell (2001) defined an ADE as any adverse event 
associated with the use of a marketed drug, whether or not that event is considered 
drug related^. This is necessary to ensure that the rare and often serious ADEs 
undetected at the phase IV clinical trials stage can be adequately detected. Much 
of the surveillance relies on voluntary reports by healthcare professional and users of 
drugs. Much of current practice in the area of Pharmacovigilance uses reports gen-
erated via spontaneous reporting systems (SRSs). These include the WHO database 
and the United States Food and Drug Administration (FDA) database as well as 
^In Trontell (2001) a serious ADE is defined as the occurrence of any of a set of specific outcomes, 
regardless of dose, including death, life-threatening ADEs, hospitalization or the prolongation of 
hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, 
or other situations in which intervention is required to prevent the occurrence of one of the preceding 
events. All other ADEs are defined as nonserious. 
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many other national regulatory agencies. The aim is to detect and act upon as 
quickly as possible any potential ADEs. There have been constant advances made 
in this area due to the rising interest in drug safety. Improvements in handling 
and storage of reports and the advent of electronic data transfer have also vastly 
improved the ease with which analyses can be made. The FDA uses a network of 
data resources to supplement detection of ADEs via the Adverse Event Reporting 
System (AERS). These data resources can be used to amplify, validate, and quantify 
ADE signals and then compare them to their expected background occurrence in the 
population. Use of additional databases and perspectives will improve the ability to 
detect ADEs in all settings, including the pediatric population, and to monitor risk 
management efforts to curtail the occurrence of known ADEs. 
Many good accounts of Pharmacovigilance have been published, including Lindquist 
et al. (1999), O'Neill & Szarfman (2001), Szarfman et al. (2002), Jones (2001), 
Amery (19996) and Amery (1999a). 
1.3.2 The Need for Post Marketing Surveillance 
The main role of post-marketing surveillance in general is to complement clinical 
trials and attempt to discover the rare and serious side effects which are not labelled. 
Most monitoring systems tend to be designed to achieve this objective. Various 
guidelines have been put forward to make the practice as scientific and ethically 
minded as possible. We have already mentioned many of the problems associated 
with clinical trials and the need for an effective system of drug safety monitoring. 
We now summarise some of the issues giving rise to the need for post-marketing 
surveillance: 
• There is a deficiency of clinical trials and the need for assessment in the pop-
ulation at risk, in particular the long term assessment of drug safety and the 
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assessment of rare events. An ongoing surveillance program is necessary to 
cover these aspects. 
• There is a need for an inexpensive and effective way of maintaining a monitor-
ing system. This system should be carried out independent of the pharmaceu-
tical companies and as such is free of the pressures that can affect the efficiency 
of clinical trial results. Clear guidelines can be suggested and maintained in 
this case for the best interest of science and ethics. 
• There is a need for a way for users and medical practitioners to effectively 
report side effects and to change the method of prescription in the event of 
any serious risk of treatment. Many instances of historical disasters could have 
been avoided with the introduction of a system of rapid alerts. 
• There is a need for an international safety surveillance system which is not 
based on companies and practices. This will require the support of the phar-
maceutical industry and moreover the introduction of a more integrated phar-
maceutical market. In Europe there are some prospects of this occurring 
although there remain many difficulties. 
1.3.3 Issues in Post Marketing Surveillance 
Although it seems an intrinsically important idea to monitor ADEs caused by drugs 
after marketing, the level of reporting throughout Europe has been relatively low. 
This has been well documented and the estimate is that only somewhere between 
10 — 25 percent of reactions are reported and these tend to consist mostly of well 
known ADEs. This can be attributed to various reasons, including the following: 
• Lack of public awareness about the role of Pharmacovigilance and ADEs. 
Many people simply do not realise that they can report suspected ADEs or 
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have no viable means to do so. This is especially true in certain countries 
where drug safety awareness is very low and there are no organised bodies to 
push for more public education in this area. 
• In Europe, the lack of a single unified pharmaceutical market means that 
disparate regions have different practices and guidelines. International safety 
surveillance bodies find this situation quite difficult since one has to take into 
account different incidence rates which cannot be easily merged without con-
sidering some hidden factors. 
• The notification of ADEs by healthcare professionals can be unsystematic. 
This leads to many people being kept somewhat in the dark on crucial issues 
of drug safety. In certain countries this lack of good communication can be 
particularly severe. 
• Many countries simply do not maintain a spontaneous reporting system or such 
systems are inadequately maintained. This is clearly an undesirable situation 
but it is rather common. Moreover, as a result of this, international monitory 
organisations have considerable difficulty in integrating data from disparate 
geographical regions. 
• The emphasis placed on drug safety can vary considerably across countries 
and practices. Many countries do not even acknowledge this major issue and 
consequently any necessary actions are neglected. There have been some ini-
tiatives in pushing for a more effective international drug monitoring system 
but the situation at present is not ideal. 
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1.4 T h e Role of D a t a Mining in Pharmacovigi-
lance 
Data mining methods have emerged to define associations in many types of databases. 
Specific methods include artificial neural networks, Bayesian probabiUty approaches, 
genetic algorithms, decision trees, nearest neighbour methods, rule induction, and 
new data visualization techniques. Much of the attention in post-marketing surveil-
lance has been paid to the process of signal detection, with some recent advances as 
well as improvements on the older methods^. The signal detection process is vital to 
safety surveillance. To evaluate the safety of a drug after detection, vast resources 
are required and this can be both expensive and time consuming. While in contrast 
the signal detection stage is relatively inexpensive and fast (one advantage of a spon-
taneous reporting system is that it is relatively cheap to maintain). Consequently 
improvements made here can lead to a significant reduction in follow-up work. 
The key to reducing the amount of follow-up work is to reduce the number of 
false positive signals (but hopefully not at the expense of detection power). It can be 
difficult to do this via an improvement in the current methodology since any method 
is highly dependent on the data available (which in this case can be quite poor). 
A viable alternative is to invest in data mining methods which will improve the 
understanding of the data and thus lead to improved ways of detection. In particular, 
it is to be hoped that data mining can significantly improve the understanding of the 
baseline data (structures intrinsic in the data) and so overcome the shortcomings of 
the data quality. We will now discuss this in further detail in the following sections. 
^Evans (2000) accounted that "Statistical methods for utihzing these data have been described 
for a long time, but have not been well used". 
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1.4.1 Introduction to Data Mining 
Data mining has enjoyed a surge in popularity in recent years, due to the fact that 
it has been able to find solutions in many diverse areas of science. In particular, 
areas such as physical sciences, social science and computational sciences have seen 
many techniques emerge that have been able to solve problems previously proven 
impossible to investigate. Along with this emergence much hterature have emerged 
which seek to quantify data mining more precisely. Some of the most important 
ideas can be found in Hand et al. (2001), Hand et al. (2002), Hand (1998) and Hand 
et al. (2000). 
1.4.2 The Need for Data Mining 
To better detect signals, it is imperative to better understand the data. To this end 
data mining is ideal for making use of information in the data to explore structures. 
We can give the following reasons for the suitability of data mining to the subject 
area: 
• The data sets tend to be large and standard analyses are difficult to utilise. 
There is scope for many data reduction techniques. In particular, in the case 
of contingency table analysis (which will be described later), the table in this 
case can be very sparse and so traditional hypothesis generation methods are 
not always applicable. 
• Data quality is often quite poor. Many types of analyses will not work well 
against such poor data. Data mining contains many techniques for handling 
poor data quality and it is often the case that a rather ad hoc method (but with 
good understanding of the data) will work better than a more theoretically 
sound method. 
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• Extra information is available for safety data (simple examples would be clas-
sifications of drugs and ADEs). Much of this information can be utilised to 
discover interesting structures (both local and global) about the data. Data 
mining techniques are ideally suited to explore these structures. It should give 
a lot of insight into the data to perform certain types of exploratory analysis 
to help to better understand the data. 
• External forces can often affect the way in which the data behaves. In keeping 
with the last note, this is another case of interesting structures and trends in 
the data, but from a different standpoint. Again data mining techniques can 
be used to discover these structures. 
Recently there has been markedly more interest in data mining techniques to 
explore the safety databases. Lilienfeld (2004) delved into several interesting issues 
in this regard. In particular, there has been a call to establish a more systematic 
approach to this area and to discover whether a general data mining approach has 
more to offer than the current collection of rather restricted methods. 
A thorough discussion on data mining can be found in Hand et al. (2001)^. 
1.4.3 Potential Improvements 
In practice, the safety detection analysis involves a hypotheses generation process. 
The problem is to look for ADEs which exceed some threshold (anomalously high 
count) beyond which action needs to be taken. How such thresholds are set tend 
to be rather arbitrary and many practices have individuals requirements based on 
experience and preference. 
An alternative way to look at this is that we are looking for unknown (unsu-
pervised) anomalous patterns. In particular we are interested in small, localised 
^Chen & Liu (2004) gave an account of the aspects of data mining applied to information 
science. 
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anomalies since it is likely that larger patterns (or the more obvious patterns) will 
tend to point to ADEs which are common and already known. It is here that data 
mining can be an invaluable tool in identifying and analysing these anomalies. In 
common with most data mining applications, we are looking for localised patterns 
of interest in the data. 
While there have now been marked improvements made in the collection and 
storing of reports on ADEs, the development of statistical techniques to explore 
these databases is still somewhat in its infancy. Although there have been some 
recent advances in Bayes and Empirical Bayes based methods, as well as the odds 
ratio (OR) based methods, much still relies on examining case reports. 
Furthermore, as mentioned, we are typically faced with relatively large data sets 
in post-marketing surveillance. Data mining is particular well suited for explor-
ing such large databases. Hand et al. (2001) described data mining as "searching 
for global and local patterns of interest that exist within large databases", such 
that conventional statistical techniques are not well equipped to deal with. This is 
precisely the objective here. 
Much work is still to be done in this area. Current practices are varied and there 
does not seem to be an underlying principle behind this practice. Furthermore, 
there do not seem to be any rules regarding good practice in the area and as a 
result various practices use various methods. This has led to a proliferation of 
methods which leaves one rather confused as to how to approach the problem at 
hand. The methods themselves do not seem to significantly improve on one another 
at a practical level and so much of the decision making is left to one's preference. 
We believe that in searching for such patterns of interest, the use of ratio based 
methods (described in section 3.2) can have some disadvantages. In particular there 
seems to be no specific way of making the full use of all information available, some 
of which can be very useful. The lack of more detailed information precludes the 
26 
possibility of developing a more systematic approach to the subject area. So as 
a preliminary comment, we believe that we need to establish some global or local 
structure with which we would be able to establish richer models. This does not 
necessarily mean more complicated models and indeed it is preferable to look for 
simpler models due to the size and poor quality of the data. That said, however, 
many techniques are available in data mining and it will not be at all straightforward 
to decide on the appropriate path. Herein lies our challenge, and the scope of such 
work presents much excitement. This will be discussed further in the subsequent 
chapters. 
1.5 Brief Descript ion of t he D a t a 
In this section we will give a brief introduction of the data sets that are available, a 
full review of the data will be given in the next chapter. 
The data comes from the following sources: AERS which consists of MED-
WATCH reported events in the United States, the General Practice Research Database 
(GPRD) which consists of events reported via patient visits to the general practi-
tioner, Oceans which is a GlaxoSmithKline (GSK) internal reporting system, the 
HIF (Health claims by plan members registered with specific HMOs, 17M patients). 
The adverse event reporting system collects data through spontaneous reports 
by users of all drugs. It is particularly well configured to detect rare events, where 
the background incidence is typically in the range of a few cases per million people. 
However, it does suffer from problems of under-reporting (van der Heijden et al. 
(2002)) and the lack of accurate baseline information. It must also be said that 
reports to AERS may not contain actual diagnoses, but rather the assumptions of 
the patients themselves, so that we cannot place implicit reliance on them alone. 
Trontell (2001) gave a comprehensive description of AERS. 
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The Oceans database has some 4 milhon case reports. It is of better quahty than 
the AERS database. While in the AERS database reporters are given the option of 
indicating the drug(s) they think are associated with an event, the Oceans databases 
require that one drug only is indicated with each event (still by the patient's own 
assumption, rather than concrete diagnosis). This means that it is much easier to 
associate drugs with events and leads to considerably simpler analysis. 
The GPRD database is the registered patient medical record database. Currently 
it contains some 4 million patients and some 80 million events. This database is 
considerably richer than the others in that it does not rely on voluntary reporting of 
events and therefore does not suffer from many of the problems associated (under-
reporting etc.). However, the database is not oriented towards the purposes of 
research and great care must be taken when extracting data from this database. In 
particular, it can be difficult to associate drugs with events. 
1.6 Thesis Outl ine 
We have introduced the reader to the area of Pharmacovigilance and in particular 
post-marketing surveillance. We have mentioned the objective of the field and at 
the same time many of the shortcomings. Improvements are certainly needed and 
we hope to illustrate in the rest of the thesis how data mining techniques can be 
applied to this end. 
The rest of the thesis is organised as follows. Chapter 2 will give an in-depth 
discussion of the data used in the area. We describe the traditional form of the data 
used to detect ADEs and we will also describe a more recent development using a 
new kind of database to the traditional approaches. 
In chapter 3 we will describe the various methods used in the area of safety signal 
detection. We will describe the ratio based methods and then give a comparison of 
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these methods. We will also apply these methods to a real example and compare 
the signals generated. 
In chapter 4 we introduce a new approach to detecting signals. We discuss the 
motivation behind the new approach, and the steps needed to arrive at practical 
conclusions. 
Chapter 5 will describe the basis and ideas of the new approach, concentrating 
on the generation of a distance metric. We describe the ideas of profiling a drug 
or an ADE such that we can measure the similarities among drugs and ADEs. 
We will describe the basic ideas of the profiling approach and discuss the various 
considerations we need to take into account. We will then describe and compare 
a variety of distance metrics for the purposes of measuring the similarities in our 
particular type of data. 
Chapter 6 will discuss data mining software. These include some major packages 
which have been maintained over many years and are consequently very mature, 
some more recent packages as well as some very application specific packages. 
In chapter 7 we will discuss new data mining techniques which can be applied in 
the new approach. Mainly a pattern discovery tool called Peaker is introduced to 
identify modes in a data set. Peaker has the advantage of being simple to compute, 
intuitively clear and easy to extend to higher-dimensional space. 
In chapter 8 we will utilise all the methods discussed in the previous chapters in 
order to perform the anomalous signals detection using the new approach. Under 
the new approach, we will use distance metric obtained using the chemical properties 
of drugs and analytic properties of drugs and ADEs. We will use Peaker to detect 
the anomalously high concentrations of side effects and also compare the signals 
obtained under the new approach to that obtained using the traditional methods. 
Finally the summary of the results and options for further research will be dis-
cussed in chapter 9. 
29 
Chapter 2 
Summary of Data 
In this chapter we describe the traditional form of the data used to detect ADEs. 
We will also describe a more recent development using a new kind of database to the 
traditional approaches. The data is variously known as Pharmacovigilance, post-
marketing or safety data. Collection of the data is through consumer reports on 
post-marketed drugs. As such, there are many problems associated with this form 
of data collection and we will outline most of the difficulties in the ensuing sections 
(Lilienfeld (2004)). Many of the major issues in the area of Pharmacovigilance arise 
as a direct result of the data collection process and the different variants of this 
process. 
2.1 B ackgr ound 
The spontaneous reporting system was introduced in the United States in the early 
1950s, expanded in the early 1960s and has remained largely unchanged to the 
present day. In the UK, a similar scheme (known as the Yellow Card Scheme) was 
introduced in 1964 in response to the thalidomide tragedy, which collects voluntary 
reports of suspected ADEs submitted by various sources. This is currently main-
tained by the MHRA, which replaced the Medical Devices Agency and the MCA 
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in 2003, and is responsible for monitoring the safety of medicines in the UK. Over 
400,000 reports have been submitted since the advent of the Yellow Card Scheme. 
In many European countries, however, the importance attached to safety monitoring 
is somewhat neglected and recently attempts have been made to harmonise the re-
porting methods across Europe (which is one of the problems facing the unification 
of a single European pharmaceutical market). One advance in this regard is the 
advent of the Medical Dictionary for Regulatory Activities (MedDRA) which is an 
international medical terminology now in wide use. We will describe the MedDRA 
in section 2.2.2. 
While the spontaneous reporting system has been undoubtedly useful in the 
monitoring of suspected ADEs, there have been various shortcomings raised (we 
will describe these in the succeeding sections). More recently there has been a 
great deal of interest devoted to an alternative database called the GPRD. The 
GPRD is currently world's largest database of anonymised longitudinal medical 
records from primary care and comprises of some 3 million patients. The GPRD is 
also maintained by the MHRA and offers a genuine alternative to the spontaneous 
reporting databases (SRDs). It is both richer and more reliable in terms of the data 
collected, although there are many difficulties in making good use of such data for 
the purposes of adverse event signal detection. We will describe the issues associated 
with the GPRD in section 2.4. 
2.2 Spontaneous Repor t ing Database 
Spontaneous reports are useful aids for signal generation, but their volume can be 
overwhelming, and it is important to assess them using a numerical and objective 
approach. The usual solution is to obtain usage data for the drug in order to as-
sess incidence. Statistical methods have been used to assess reports in this context. 
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There are problems with this approach in that sales data do not necessarily mea-
sure usage, and even with prescription data being available accurately there are 
a number of biases associated with spontaneous reporting. The rate of reporting 
is very variable over time, with the highest rates occurring when a drug is newly 
introduced. Another approach is graphical, where the so-called safety profile is a 
graph showing the numbers of reactions for a particular drug in medical categories 
called system organ classes (SOCs). While this is helpful for prioritisation in some 
instances, it tends to overemphasize the reactions that occur most frequently. It is 
not itself numeric and does not have an obvious comparison group. The use of pro-
portional reporting ratios (PRRs) can be seen as a numerical version of the safety 
profile. A similar approach is used in classical epidemiology with death data, where 
denominators are unknown or uncertain proportional mortality ratios. The basic 
idea is to use a 2 x 2 table. The rationale for using this is that the proportion of 
reactions that are reported on Yellow Cards is relatively constant over time. Since 
the 1960s when Yellow Cards were introduced, the number of suspected ADEs re-
ported per year has risen, with a peak in 1992. The UK database of these reports 
is called ADROIT (Adverse Drug On-line Information and Tracking system), and is 
maintained by the MCA. While the number of reports has changed, the proportion 
in different system organ classes has remained relatively stable. While the use of 
a test of statistical significance should not be taken as having an exact meaning in 
this context, it does aid interpretation in allowing for the likely effect of chance on 
the PRR. It also helps in the screening process for identifying signals that should be 
investigated as a priority when there is a small number of reports received. The PRR 
is of greatest use in monitoring drugs, especially those which have recently been in-
troduced to the market, since safety information on them is inherently limited. The 
number of statisticians who have applied their creativity and effort to the problems 
of assessing drug safety is notably fewer than the numbers doing so for studies of 
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efficacy. Large randomized pragmatic trials will undoubtedly help, but the motives 
for funding these do not exist in companies, and the regulatory authorities do not 
have a role as funders of such studies. 
2.2.1 Overview 
The conventional form of data collection is through that of a spontaneous reporting 
database, in which data is received in terms of reports filled in by drug users and 
medical practitioners who suspect an ADE. There are many separate forms of this 
database across different geographical regions, of which the main ones are: 
• The AERS maintained by the FDA in the United States. 
• The WHO database which is maintained by the Uppsala Monitoring Center. 
• The database on the Yellow Card Scheme maintained by the MHRA. 
• Oceans which is an internal database maintained by GSK. 
The basic idea is the same in most of these systems, with a few semantic changes. 
To illustrate. Figure 2.1 shows a MED WATCH voluntary report form as collected 
by the AERS database. 
The MEDWATCH form allows two suspect drugs (primary and secondary) to be 
entered. This can lead to quite messy data in terms of drug-event association. The 
problem is that whilst it is in principle desirable to list a number of the suspected 
drugs, in practice it is difficult to look for such interactions and often such multiple 
interactions complicate the analysis. Moreover, a mixture of single and multiple 
drugs interactions gives very unreliable and confusing baselines. This has led to 
many practitioners only using the primary suspect drug. The Oceans database only 
allows one suspect drug to be entered on each report and is therefore a much cleaner 
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Figure 2.1: MED WATCH Voluntary Report Form 
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database. On the other hand, having two suspect drugs does permit investigation 
into drug interactions which constitute a prominent question in Pharmacovigilance. 
Each database has its own set of guideUnes (for a comprehensive description of 
the guidelines of the AERS database see Trontell (2001)). Bortnichak et al. (2001) 
discussed the use of spontaneous reporting databases in safety surveillance. 
2.2.2 Coding Dictionary 
When using a spontaneous reporting database, the encoding of ADEs is an impor-
tant component. As already mentioned, the most widely used coding dictionary is 
the MedDRA although other older dictionaries are still in use which include the 
WHO Adverse Reaction Terminology and the Read-OXMIS dictionaries (although 
the Read-OXMIS has now been converted to MedDRA, there are still some terms 
which have not been mapped). We will center our discussion on the MedDRA given 
its international acceptance. 
The MedDRA includes five levels of hierarchy, which are (from the top down) the 
System Organ Classes (SOCs), High Level Group Terms (HLGTs), High Level Terms 
(HLTs), Preferred Terms (PTs) and the Lower Level Terms (LLTs). The following 
table contains the number of terms at each level, as published in Brown (2002). The 
SOC 26 
HLGT 333 
HLT 1685 
PT 14287 
LLT 51083 
Table 2.1: The MedDRA Hierarchy 
MedDRA is multi-axial, which means that child leaf terms may be contained in more 
than one parent leaf term. This means that a distinct classification of ADE groups 
according to the higher level class is impossible and as such it is difficult to carry 
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out hierarchical analysis. When looking for specific ADE signals it is most common 
to look at only one level of MedDRA and analyse using the terms at this level. 
Additionally MedDRA is not set up for research purposes but gives more leverage 
to other considerations such as convenience of terminology for medical practitioners. 
In this way it is again not suitable for grouping families of ADEs, especially if one 
expects these families to exhibit some inherent similarities with regards to their drug 
response. 
The most important issue with regards to the area of safety signal detection 
concerns the level of the dictionary which one should use to mine for associations. 
Clearly this is a crucial aspect since the generality of ADEs which one uses plays 
a decisive role in determining the signals which one can detect. The whole issue 
is as yet unresolved and it is rather a matter of choice as to precisely which level 
one should use for specific types of signal detection. Most practices tend to use the 
PT level for any analyses which is widely considered to offer the most flexibility 
in terms of a balance between being too general and too specific. Moreover, many 
practitioners attempt to use customised levels derived from the MedDRA using some 
certain set of criteria. We will see in the remainder of the thesis that in a way this is 
precisely the problem that we try to overcome, by designing a more flexible method 
which automatically and adaptively determines the choices that we would otherwise 
have to make in the above. 
2.2.3 Strengths and Weaknesses of Spontaneous Reporting 
Systems 
The spontaneous reporting system can be particularly suitable for the purposes of 
drug safety monitoring. We will now hst some of the strengths below; 
• First and foremost the SRS takes into account all patient groups in contrast 
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to clinical trials. This is one of the main advantages of the SRS set up and 
most other databases cannot accomplish the same. 
• It has relatively low set up and running cost since it relies on voluntary report-
ing. Compared to a cUnical trials study, which uses cohort populations which 
can be very expensive to set up, the SRS is considered very cheap. Moreover, 
the set up allows for constant and long term monitoring of all post-marketed 
drugs. 
• The ideal scenario for the SRS is to allow for rapid (in a temporal sense) drug 
alerts. One would hope that reports would be received at the advent of a new 
ADE and quickly lead to follow-ups. Moreover, the SRS is unlikely to cause or 
influence prescribing behaviour (unlike clinical studies) and so it is reasonably 
safe to assume a constant incidence rate over time. There are some special 
circumstances for this to be not true but it can be taken as a general rule. 
However, there are many difficulties associated with the system. We have al-
ready mentioned some of the problems associated with the spontaneous reporting 
databases in the above sections. Some of these may appear rather intuitive but 
there are many other problems which are not at all obvious. Note that we are only 
concerned with the problems arising as a direct result of the data collection process 
itself and consequently the database system itself. We do not mention the problems 
of applying specific methods to the data. We will look into these inadequacies of the 
data in the next section. However, it is worthwhile to keep in mind that many of 
the method specific problems can be traced to the issues mentioned in this section. 
We will now list and explain in more detail the various difficulties which can 
arise when using the spontaneous reporting databases; 
• There is a general lack of a usable baseline (number of patients exposed to a 
drug) for the reports collected and this severely hampers the signal detection 
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process. In simple terms there is generally no sensible estimate of the num-
ber of prescriptions which underlie the numbers of reports received. Clearly, 
without such baselines, it is difficult to precisely quantify the severity of any 
ADRs. 
• As we can see from the MEDWATCH report form, some reports are only 
based on patients' suspicions. This clearly leads to inaccurate reports and 
much follow-up work has to be done to verify the claims. For rare events 
in particular, where there may only be a few reports collected, it is difficult 
to be sure of the validity of each report. Of course in the majority of cases 
the reports come as a result of medical diagnosis, but the proportion of non-
diagnosis is by no means insignificant. With most practices, the attitude is to 
take into account every report if it contains a rare and severe event. As such, 
a rather arduous process is required to back up the initial data collection. 
• Duplicate reports can and often do arise. The most common occurrence of this 
problem is attributed to the same ADE being reported by multiple sources (the 
patients, doctors and pharmacists), although other reasons (multiple reports 
by the same source) are also possible but generally much more infrequent. For 
rare or severe events this can be a major problem since only a few reports are 
required to constitute a signal. Of course, as mentioned in the previous point, 
a validation process can pick up such inconsistencies but any such false signals 
cause waste of valuable resources. 
• Because of the reporting nature of the data, it is often the case that external 
forces (such as media coverage) can cause a dramatic surge in the number 
of reports filed. Often this can cause enormously disproportionate levels of 
the signals detected. As yet this is a rather unexplored area of research and 
the precise extent of the differences this can cause is difficult to quantify. 
38 
Precise temporal aspects of the data are also rather difficult to obtain in some 
databases and this further complicates the analysis. 
• The problem of under-reporting is another concern. Whilst erroneous reports 
need careful validation, it is much more common for patients to simply not 
report anything at all. The general attitude tends to be that this is not as 
serious as receiving a false report. But clearly this leads to rare events being 
undetected. Research into this area is as yet somewhat undeveloped and the 
precise effect of under-reporting unexplored, van der Heijden et al. (2002) gave 
a quantitative account of the under-reporting problem. 
• We also need to consider the level of the coding dictionary to use such that 
it best reflects on the detection of rare events. Currently the PT level is the 
most widely used in Pharmacovigilance, although this is considered by some 
to be too fragmentary whilst the HLT level is too general. Brown (2002) gave 
an in-depth account of the effect of coding dictionary on the signal generation 
process. 
• Practices are different across geographical regions and institutions. This can 
lead to very different signals as varying background rates arise. The full effect 
of this on the signal detection process is as yet unclear. It is also the case that 
different practices operate under different guidelines (for instance, this can be 
in terms of methods employed, thresholds or data preparation) and signals 
detected under one practice may well be lost under another. Some effort has 
been devoted in achieving a more unified approach to signal detection across 
these different practices and in researching into the differences involved but 
this is as yet a rather grey area. 
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2.3 Processing t h e Raw D a t a 
The raw data itself would initially be in report form. This is subsequently processed 
into a tabular form which comprises of each report crossed by a variety of attributes 
(most of these attributes are patient and report information such as sex, gender and 
time of report). 
To perform signal detection, the traditional type of analysis (we will describe a 
review of these methods in the next chapter) is to look for abnormally high counts 
for combinations of drug and ADE. This can be done in a number of ways but by 
far the most common is to arrange the data in a large categorical contingency table 
consisting of drugs against ADEs. Each cell of the contingency table would then 
represent the number of times (number of reports) that an ADE is associated with 
a drug. As mentioned earlier, in certain SRSs, the associations are clearly defined 
in that only one suspected ADE is permitted to be entered. In these instances, 
there is a clear definition of a single count (single association) for that drug-ADE 
cell and the task of setting up the contingency table is clearly straightforward. In 
other SRSs, multiple suspected ADEs and drugs can be reported and here the task 
of looking for associations is more complicated. In the remainder of this section 
we will describe how to transform the reports of multiple associations to that of a 
categorical contingency table. 
In the instance when there exist multiple associations in the reports, one has 
to count all the instances of a particular ADE being associated with a particular 
drug. To do a brute search for such associations would be computationally quite 
expensive, especially if one is also interested in higher-order associations. 
The general problem comes under the heading of Association Analysis. The ini-
tial application was that of the market basket problem, whereby one looks for com-
binations of items that tend to be bought together in large supermarket databases. 
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There has been a great deal of effort made to invent fast algorithms to tackle this 
problem. The apriori algorithm is one example of a fast algorithm developed to han-
dle large datasets (for literature on association analysis see Agrawal et al. (1993), 
Agrawal & Sikrant (1994) and Hipp et al. (2000)). 
2.4 T h e G P R D Database 
2.4.1 Overview 
The GPRD currently contains some 3 million active patients and is the largest 
database of its kind in the world. In particular it contains the prescription and 
event history of each patient and thus is a longitudinal database as opposed to 
the spontaneous reporting databases. The GPRD contains much richer information 
than the spontaneous reporting databases. It contains the exact baseline for each 
drug which is an advantage over all traditional spontaneous reporting databases. 
Moreover, the information is collected through medical practitioners which makes 
the GPRD more reliable. Other information is also available through the GPRD 
which ranges from the basic (such as gender, age, registration detail and other 
patient specific data) to the very detailed (such as free-text which allows the medical 
practitioner to input manual text). 
Undoubtedly there is potential in the GPRD for it to be usefully employed in 
the context of mining for safety data. Currently the GPRD is mainly used for 
population-based cohort studies of various drugs. Its use as a Pharmacovigilant 
database is yet to be clearly defined. This is partly due to the difficulties that one 
can encounter when mining the GPRD in this way (we will describe this in the next 
section). 
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2.4.2 Strengths and Weaknesses Associated with the G P R D 
In this section we will discuss the main strengths and weaknesses of the GPRD, as 
compared to the SRSs. Wong (1999) and Waller et al. (1996) gave introductions to 
the GPRD. We will list some of the strengths below; 
• The database holds exact baseline for each prescribed drug as well as the exact 
number of patients experiencing an ADE. This by itself is already enough to 
justify the use of the GPRD. Moreover, the rate of associations is much higher 
since we no longer rely on voluntary reporting which, as mentioned, can be 
very low. 
• Potentially it is possible to obtain quicker and more up to date reports, since it 
is likely that healthcare professionals will report quickly given their improved 
awareness of drug safety. 
• Other information is also available to supplement simple associations. Some of 
this information can be quite useful, such as dosage levels and time of prescrip-
tions since these can be used as stratifying variables. Moreover, the GPRD 
contains all medical records over time and so can be used to study various 
factors (examples are multiple associations, the effects of external forces and 
changing levels of prescriptions). 
However, the GPRD has a new set of problems associated with it. Clearly the 
way GPRD is set up makes it best suited to cohort studies and to use it for the 
purposes of post-marketing surveillance requires some careful thought. Below we 
will list some of the difficulties associated with GPRD: 
• The initial difficulty lies in how to associate drugs with causing particular 
events. Unlike the SRSs, there are no suspected drug-ADE associations so 
that any associations are speculative at best. Given that we have an enormous 
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amount of data for each patient, this is by no means an easy task. There 
are also various other considerations to take into account with regards to 
associations. We will list some of these below: 
— Intervals of association - Even if a patient is taking only one drug for a 
sustained period of time, there is still the question of how much of the 
time period we need to take into account when looking for the events 
caused. 
— Switching between drugs - Some patients switch between drugs and it is 
difficult to have a distinctive cut-oflF point for the switch. In particular, 
the problem lies in when one decides that a patient is clear of the previous 
drug and onto the next. This involves obtaining knowledge with regards 
to the incubation periods of various ADEs and this is clearly not at all 
an easy task and is in practice impossible to implement. 
— Discontinuous prescription - Truncated courses of treatment occur regu-
larly through each patient history. A central issue for such information is 
whether it is advisable to mine events in all these disparate time intervals 
or to take one time interval only. Whilst it may seem desirable to take 
into account all the history of a patient, it is highly likely to give rise to 
duplicate events. 
The GPRD applies only to primary care patients and does not apply to hospital 
care. There can often be poor communication between primary care records 
and hospital records and certain information can be lost. Hospital drugs or 
treatments are also not available so that not all products are encompassed. 
There are various amounts of prescription and dosage levels (as well as the 
inherent free text contained in GPRD, which is not shown here). This is 
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obviously important in determining the length of time a patient is taking 
a drug. We can also see the disparity of the information among records. 
Therefore we need some way of mining for the text information in these records. 
2.4.3 Mining the G P R D Database for the COX-II Data 
It is possible to mine for very pure drug event associations so as to disregard certain 
suspected drug interactions, take only continuous courses of prescription and to 
ignore events which have already occurred in the patients' previous histories. In 
this section we will outline an attempt to mine the GPRD database. The data used 
is the records of 1,000,000 patients who have been prescribed the COX-II drug. First 
we define a continuous course of treatment as one for which the patient is taking one 
drug (one variant of COX-II). The time at which each prescription expires before 
the next treatment is calculated as p^ escr^ mn^ penod _ Additionally we set a 28 day 
tolerance period (the majority of the prescription periods being 28 days). So we say 
that a patient is on a continuous treatment if there are no breaks in the treatment 
such that the time between two prescriptions exceeds 28 -f- days. The level 
of dosage is obtained from the Dosage column. 
For each patient, we take the largest contiguous block of treatment and ignore 
others. This allows us to leave out carry-over effects whereby the events occurring 
for one treatment can be attributed to the previous treatment. Additionally we will 
ignore switching for the time being and investigate pure treatments containing one 
drug only. 
Recent research has revealed a connection between COX-II drugs and cardiac 
events and these constitute the major aspects of interest. In this case, there is a 
marked difference in terms of taking into account patients that are on a prescribed 
course of Aspirin since Aspirin is known to suppress cardiac events. We will therefore 
stratify patients who are on a consistent course of Aspirin and those who are not. 
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Additional factors to take into consideration are stratification according to dosage 
levels of COX-II drugs. This is somewhat complicated by the different levels of 
dosage throughout one contiguous course of treatment. We will therefore take the 
mean dosage level in any one treatment. There are three main levels of dosage 
around approximately 25, 100 and 200 milligrams so we will stratify with these 
three levels and discard other levels. 
All this leaves approximately 55% of patients from the initial 100,000 who quaUfy 
for with our criteria of taking COX-II drugs. We can then mine for the ADEs 
associated. In this particular instance, it will be interesting to initially restrict the 
ADEs to cardiac events since these are the events of interest. We can also add a 
temporal element to these events and mine for ADEs at 2-month intervals. This 
can reveal interesting tendencies in the ADEs since it is known that some associated 
events have particular incubation periods. 
2.5 D a t a Issues 
As described in section 1.5, the data sets involved in this project are typically large, 
involving contingency tables with millions of cells. This presents many problems of 
its own, such as follows: 
1. Computational efficiency - This is particularly relevant and we have to decide 
carefully which techniques are computationally viable. In particular, a large amount 
of programming is required as most existing software packages are not well equipped 
to deal with such vast data sets. Such programming must always be carried out with 
efficiency in mind. 
2. Dimensionality - As the size of the dataset increases, so typically do the 
dimensions used to represent the data. The curse of dimensionality is well known 
and this can cause very different interpretations of the data in terms of distance 
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between points. Points are further away from each other in higher dimensional 
space. 
3. Visual exploration - Large data sets can be difficult or impossible to inspect. 
Many simple plots which can be extremely useful in giving an initial impression of 
the data may simply not be adequate. It is also difficult to pick out individual points 
among a mass of other points. 
4. Data formatting and checking - Putting the data into the right format for 
analysis can be time consuming and may require some careful thought. Moreover, 
any corrupted data is hard to pick up and in many cases we may have an idea only 
after an analysis has been carried out. 
We need to give careful thought to all these issues before carrying out each 
analysis. 
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Chapter 3 
Review of Methods 
In this chapter we will describe the various methods used in the area of safety 
signal detection. Since the advent of the SRS, there have been some advances in 
methodology. However, many of the techniques still revolve around making use of 
ratio based measures to give meaning to the degree of severity of each drug-ADE 
combination. In this, there has been no significant improvement over the years. 
Moreover, there is still a sense that most methods cannot be relied upon too heavily 
and stringent follow up work is needed in the case of each signal. 
For the rest of this chapter, we will first describe the ratio based methods and 
then give a comparison of these methods. We will also apply these methods to a 
real example and compare the signals generated. 
3.1 Nota t ion 
We first define some notations^, which we will use for the remainder of the chapter. 
Assume a two-way contingency table of r rows and c columns: 
• Uij - count for cell (i, j ) , i= 1 , . . . , r, j = 1 , . . . , c. 
^For a thourough discussion of some methods mentioned in this chapetr, see Fedorov et al. 
(2003). 
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• nj. - marginal count for row i. 
• n.j - marginal count for column j. 
• n.. - total count in the table. 
' 7r<. = TT.j = 
• Pi- and p.j are the true probabilities for cell count, row marginal count and 
column marginal count respectively. 
3.2 Measures of Association 
As mentioned, most of the analyses in safety signal detection are based on ratio 
measures. This stems directly from the traditional association measures which are 
used in many areas, in particular (as an area closely linked to our problem) epi-
demiology and more generally traditional contingency table analysis. Classically, 
measures are derived which in some way estimate the ratio between the actual and 
expected number of incidences based on some initial assumptions about the data. 
In the following sections we will list some of the most widely used ratio measures. 
3.2.1 Discrepancy Measures 
In traditional contingency table analysis, most of the interest centers on testing the 
hypotheses of independence within the table and homogeneity between rows and 
columns. These can be presented in the following null hypotheses: 
1. Independence 
Hq : Pij = pi.p.j (3.1) 
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2. Homogeneity 
Hq Pij = Pi\jP-j (3.2) 
These tests are equivalent (assuming the absence of "zero probabilities"), there-
fore we will only consider the test for independence. 
For the test of independence, the well-known test gives 
, (3.3) 
n.. 
and the Kullback Liebler divergence gives 
KL = (3.4) 
with and 2KL following a distribution with (r — l)(c— 1) degrees of freedom. 
In the case that we are only interested in the contribution of particular cells 
to the totals (3.3) and (3.4), we can define each cell contribution for the two tests 
respectively as 
n2 _ {Pij -Pi-P-jf 
and 
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which can be estimated by replacing pi. and p.j by their maximum likelihood 
estimators tTj. and tt.j to give 
a2 _ (TTij -
ij 
TT^ .TT.j 
and 
KLi j = TTij In • 
TTi.TT.j 
The above can be used to indicate the measures of association between a particular 
row and column. In the case of adverse event detection this is naturally applicable 
since we are only interested in each cell and not the overall table. 
3.2.2 Ratio Measures 
We can adjust the discrepancy measures of the last section to suit the purposes 
of adverse event detection. Many measures of association have been proposed and 
used, leading essentially to a similar premise^. The odds ratio is a commonly used 
measure of association (Agresti (1990)). The OR is easy to interpret and represents 
the odds of an event occurring in group 1 to that of group 2. 
For a drug-ADE combination, if we have the following table, then the OR takes 
Drug present Drug not present 
ADE present 
ADE not present 
a 
c 
b 
d 
Table 3.1: Table of Presence of Drug and ADE 
^For literature in this context see van Puijenbroek et al. (2002). 
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the form 
(3.5) 
Other ratio measures commonly in use are the Reporting Ratio (RR) in Du-
Mouchel (1999) and the PRR in Evans (2002), defined by 
RRij = — — , (3.6) 
TT^ .TT.j 
and 
All these ratio measures reduce to essentially the same form when the table is 
large. The generic form is the ratio of the observed counts to the expected counts. 
Of course, there is a marked difference when the table is sparse, since it can often 
be the case that one cell can predominate in an entire row or column. 
3.3 Bayesian Approach 
A few of the more recent publications (DuMouchel (1999) and Orre et al. (2000)) in 
adverse event signal detection have used Bayesian ideas to estimate pi. and p.j. 
In particular, Empirical Bayes estimation is used to produce smoothed estimates. 
In this section we will give a general overview of Empirical Bayes and Shrinkage 
Estimators methodology as well as some of the methods applied to adverse event 
signal detection. In particular, there are generally two recognised models currently 
being applied to safety signal detection. The first is the Gamma-Poisson model 
(or a similar model called the Gamma-Poisson Shrinker (GPS) given in DuMouchel 
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(1999)). The GPS is widely used and currently is applied to the AERS database. 
The second is the Beta-Binomial Model (or a similar model called the Bayesian 
Confidence Propagation Neural Network (BCPNN) given in literature including Bate 
et al. (1998) and Bate et al. (2002)). The WHO database extensively uses the 
BCPNN. 
3.3.1 Empirical Bayes and Shrinkage Estimators 
There is a large body of literature on the subjects of Empirical Bayes and Shrink-
age Estimators, which are closely linked. Indeed, one common and widely used 
method of obtaining a Shrinkage Estimator is through the use of Empirical Bayes 
methodology. 
The most famous example of a Shrinkage Estimator is the James-Stein Estimator 
(JSE). James & Stein (1961) demonstrated that the Maximum Likelihood Estima-
tor (MLE) for the means of a multivariate normal distribution is inadmissible {i.e., 
it is possible to construct an estimator with smaller risk). The point of Shrinkage 
Estimators is that they incorporate information from many different entities to de-
scribe a single entity, thereby having smaller average risk than the MLE. Shrinkage 
Estimators, in particular the JSE, are discussed in Efron & Morris (1973), Gruber 
(1998) and Morris (1983). 
The Empirical Bayes approach has largely been stimulated by Robbins. It in-
volves both Bayesian and Prequentist approaches to statistics. One specifies a prior 
parametric form for the parameters of interest and proceeds to estimate the prior 
parameters through the data via the marginal distribution. Empirical Bayes Esti-
mators are known to have asymptotically optimal properties (for a discussion see 
Deely & Lindley (1981) and Morris (1983)). 
In our context, the Empirical Bayes approach smoothes the values of the as-
sociation measures to allow more reliable estimates for smaller sample sizes. The 
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Empirical Bayes process is repeated separately for different measures in the cases of 
higher order associations. 
3.3.2 Gamma Poisson Model 
In this section we will describe the Gamma Poisson model used in adverse event 
signal detection. The premise of the model is that data is assumed to follow a 
Poisson distribution (Po) with a prior which follows a Gamma distribution (Go). 
Assume ~ Po{fj,ij) and ~ Ga{arc,Prc)- In the posterior //„ ~ Ga{arc + 
f^ij! Pre 1) • 
The marginal distribution of Uij follows a negative binomial distribution of the 
form 
= (3.8, 
To estimate OYc and Pre, one can use the method of maximum likelihood, which 
would require the estimation of each parameter by some numerical approximation 
method. It is far more practical to use the method of moments (MM) estimators^. 
The expectation and variance of are 
= (3.9) 
and 
V{rHi) = (3.10) 
Substituting the sample mean and variance, fiij and s^, for E(nij) and Vijiij) gives 
the MM estimates. 
®In the sense of computational efficiency, although in some cases it is viable to use the MLE. 
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The posterior estimate (or Empirical Bayes estimate) for is then given by 
Similarly estimates for pi. and p.j can be obtained. 
3.3.3 DuMouchel's Gamma Poisson Shrinker 
The Gamma-Poisson model used in the last section is the basic form of such a model. 
DuMouchel (1999) used an alternative formulation of the Gamma Poisson Model, 
termed the GPS. We will now describe this alternative model. 
Assume Uij ~ Po{fj,ij) and ^ ~ Ga{aij,Pij). DuMouchel actually used a mix-
ture of two Gamma distributions for the prior, but we will just use a single Gamma 
distribution to reduce notation. 
Again we can calculate the estimates dij and through the marginal distribu-
tion, which is a negative-Binomial distribution. 
The posterior expectations of A^ - and log{Xij) are given by 
= n«) = + (1 - (312) 
and 
E{log{Xij)\Nij — riij) — Qnij''P{o:i+nij)log{Pi+Eij)+{l—Qnij)i'{oi2+'n'ij)log{P2+Eij) 
(3.13) 
where ip is the Digamma function. 
DuMouchel advocated the use of E(log2{Xij)\Nij) and ranking 
measures for signals generated by each drug-ADE combination, which he termed 
EBlog2ij a n d EBGMij respect ively. 
There is also an extension to the GPS, termed Multiple Gamma-Poisson Shrinker, 
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which is used to find signals in sets of size 3 or larger. The details can be found in 
DuMouchel &; Pregibon (2001). 
The GPS has an inconsistency, which is that although the data are modelled by 
a Poisson distribution, it assumes fixed marginal totals in the prior4. 
3.3.4 Beta Binomial Model and the Bayesian Confidence 
Propagation Neural Network 
The Beta-Binomial model assumes that ^ Bn{n..,pij),ni. ~ Bn{n..,Pi.), n.j ~ 
Bn{n..,p.j) a n d % ~ Be{aij, pij),Pi. ~ Be{ai., pi.),p.j ~ Be{a.j,/3.j), w h e r e Bn 
denotes the binomail distribution and Be denotes the Beta distribution. 
Orre et al. (2000)^ suggested that Pi. and p.j both follow uniform distributions 
over the unit interval, and to set CKy and j3ij so that 
Q!j. = Pi. = (X.j = p.j = CXij = l,/3ij = — % . (3.14) 
Pi-P-j 
Alternatively we can again estimate the prior parameters via Empirical Bayes. To 
do this, we assume that ^ P.j Pc^ l^ij — Pre 
The marginal distribution for n^- is given by 
Ac) = ( " « ) + (3.15) 
\^Tl.. J Pre) 
where B( ) is the beta function. 
We can use the MLE or the MM estimator. Again for practical purposes the 
fixed marginal total in this case points to the fact that the data are distributed as a Multi-
nomial distribution, which is inconsistent with the Poisson assumption. 
®The BCPNN described in Orre et al. (2000) uses a slightly different formulation of the Beta 
Binomial Model. This difference is similar to that between the Gamma Poisson Model and the 
GP& 
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MM estimator is preferred. The expectation and variance of 3.15 are given by 
and 
E{nij) = n , (3.16) 
^rc ~t" Pre 
+ c . „ + / 3 „ V l ' - (3 .17) 
Substituting the sample mean and variance, fiij and s^, for E{nij) and Viriij) gives 
the MM estimates for a^c and Pre- Similarly we can obtain estimates for the other 
prior parameters ar, Pr,cxc, Pc-
The posterior estimate (or Empirical Bayes estimate) for is then given by 
Aj = . (3.18) 
Tl.. ~h C^rc Pre 
3.3.5 Bayesian Nonparametrics 
We can use a Bayesian Nonparametric approach to modelling our data. We imple-
ment a Gibbs sampler in a mixture of Dirichlet process (MDP) model (for a complete 
description of the general sampling scheme see MacEachern & Muller (1998) and 
MacEachern & Muller (2000)). Escobar & West (1995) gave a mixture of normals 
formulation while Quintana (2002) presented the approach in a Multinomial con-
text. Here we will give the basic formulation of the MDP model in the context of a 
Poisson likelihood, according to the general scheme given in MacEachern & Muller 
(2000^ 
The basic MDP approach is as follow: The data has hkehhood yj ~ Po{6i) with 
prior 6i ~ G, where G is a random distribution generated by a Dirichlet process with 
base measure MGq and total mass parameter M such that G ~ D f (Go, M). Here 
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we choose the conjugate base measure Go = Gamma{a, /?) for ease of computation. 
We will now define notations: 
Let 6 = {9-1,, 9n} be the vector of hkelihood parameters. 
Let (p = {01, • • •, 0fc} denote the set of distinct 0j's. 
Let s = denote the vector of configuration indicators defined by 
Si —— J iff Oi ^ Ij . . . 5 Ti. 
Let n = {ni, .../%&} denote the vector where nj is the number of Sj = j. Gibbs 
samphng is implemented by iterative sampling from the full conditionals, and the 
full sampling scheme is as follow: 
• To resample we assign Si = j for existing cluster j with probability 
n-jp{yi), where n-- denotes the size of cluster j with 6i removed from consid-
eration and p{yi) is the posterior predictive distribution for again with 
9i removed. We assign Sj = A; + 1 for new cluster A: + 1 with probability 
In our Poisson-Gamma context, ~ NB{a,P) = r(a)rS-i) • 
• To resample (pj, we simply sample from the posterior for (f)j over all data points 
with Si = j. 
In our present context, this amounts to sampling (j)j from (j)j ~ Gammaia + 
%, /3 + ^ j/j) where the sum is over all % such that Si = j. 
• To resample M, we need to define an auxiliary function on M with an additional 
latent variable x such that pix\k, M) = Be{M + 1, n). 
• To resample all other hyperparameters, we simply use the standard Bayes 
formulation and resample from the relevant conjugate posterior. 
The MDP model is a popular one in the Bayesian Nonparametrics literature. 
Bayesian Nonparametrics has the advantage of not requiring a specific model formu-
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lation. We can think of this as modelling the data as a countably infinite component 
mixture, as opposed to some of the previous methods in Pharmacovigilance which 
uses mixtures of two component priors. Clearly we obtain a much richer model in 
this case. There are also various other aspects to this model. We already have 
clustering in the data and we can devise a test for independence in the contingency 
table and we can test for homogeneity between rows and columns. 
We are left with the task of specifying the parameters in the Dirichlet distribution 
prior. The simplest way is to specify a reasonably flat prior. We use the following 
scheme (for drug profiles): Calculate the mean of each ADE across all drugs and set 
the prior Dirichlet parameter oi* for drug i as 
oii = Xifii + (5j, 
where jii is the mean for each ADE and suitable values of Aj and 5i can be chosen. 
Initially we will simply use the same value for Aj and 5i for all ADEs. We can try a 
range of values in an empirical study. 
An obvious advantage of this approach over the DuMouchel approach is that we 
can now set prior parameters according to the importance we attach to a particular 
ADE, by changing values of A* and (5, (small values giving more emphasis to the 
data). This information can be easily obtained from lists giving the severity of each 
ADE. 
3.4 Applicat ion 
We apply the various methods to a real data set consisting of 172 drugs and 2245 
ADEs. Note that here the data is selected in such a way because of availability. In 
ideal circumstances it would be more representative to choose a data-set which has 
more balanced numbers of drugs and ADEs. We apply each of the methods (the OR, 
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the Gamma-Poisson model, the GPS, the Beta-Binomial model and the BCPNN) 
to the data. For each method we calculate the list of signals which comprise the 
drug-ADE combinations that return the highest numbers in terms of the signals 
generated. The top 40 signals for each method are generated and shown in Table 
A.l to A.5 in Appendix A. As we would expect, the high variation of the OR 
means that the highest signals all comprise of low counts (typically of the order 
l o r 2). Moreover the high variation is further confirmed by the excessively high 
numbers that make up for the signals. Perhaps surprisingly, the Gamma-Poisson 
model and the Beta-Binomial model both return as unstable signals as the OR. A 
closer inspection reveals that these signals generated by the Gamma-Poisson model 
and the Beta-Binomial model are in fact nearly identical to the ones generated 
by the OR (the actual drug-ADE combinations are the same). This means that 
there has been very little smoothing applied. However, if we examine the way by 
which the smoothing is actually performed in both of these methods, we can easily 
see that this is to be expected. We can examine the difference when it comes to 
the GPS and the BCPNN, in both of which the basic model is modified to allow 
smoothing to be applied in different ways. Note that for the BCPNN we use the 
uniform prior in this case. We can see from both the counts of the combinations 
and the signals themselves that these methods produce much more stable signals. In 
particular we notice that the counts almost entirely consist of higher numbers, which 
incidentally are much higher for the BCPNN than the GPS (this is partly because we 
are using the uniform prior for the BCPNN). From the formulation of the GPS and 
the BCPNN the results are also to be expected since the smoothing is applied to the 
baseline in both cases which would significantly reduce the problem with excessively 
low baseline value faced by the OR, Gamma-Poisson model and the Beta-Binomial 
model. On the other hand, we must consider that it is not necessarily better in 
all cases to apply smoothing to such an extent, since we are now faced with the 
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alternative problem that all the low counts are being smoothed out and the signals 
would consist entirely of higher numbered counts. We will discuss this in more depth 
in the next section. 
3.5 Discussion 
In this section we discuss the advantages and disadvantages of the methods described 
above, as well as a general summary of the whole approach. There is some literature 
which gives comparisons of the different methods, such as van Puijenbroek et al. 
(2002), Evans (2002), Meza (2003) and Fedorov et al. (2003). 
The odds ratio clearly suffers from the problem of sampling variation at low 
counts®. In many cases this leads to unstable baseline information, resulting in the 
fact that the highest odds ratios tend to be very small counts (often ones and twos). 
This is clearly unsatisfactory. Attempts to remedy this problem have been to either 
ignore the low counts or to use the Empirical Bayes based smoothing methods^. 
Ignoring the low counts has a major drawback, which is that the unknown rare 
ADEs tend to be precisely these low counts. Of the Empirical Bayes methods, the 
Gamma-Poisson model and the Beta-Binomial model with Empirical Bayes prior 
do not apply very much smoothing and are very close to the odds ratio in practice 
while the GPS and the Beta-Binomial model with uniform prior apply a lot more 
smoothing. However, what can we make of this smoothing? First of all, it has to 
be said that at large counts the smoothed estimators approach the odds ratio, so it 
is really the small counts which are affected. As mentioned, this is convenient since 
these tend to be what we are interested in anyway. The smoothing is essentially 
®DuMoucliel (1999) accounted that "Measures based on raw ratios of observed to expected seem 
too ready to select cells with very small counts". 
^DuMouchel (1999) accounted that "One way to reduce the sampling variation in RR would 
be to require a minimum value of N, such as at least 5 observations in a cell. But one needs a 
rationale for choosing the cutoff value". 
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controlled by a few prior parameters. While this works well for some applications, 
in some areas of contingency table analysis, spatial analysis (Cressie (1993)) and in 
particular spatial disease mapping (Group (2000), Marshall (19916), Manton et al. 
(1989), Marshall (1991a) and Hills & Alexander (1989)), these tend to involve much 
smaller datasets where one would be interested in better estimators or in tests for 
the entire data set such as the test for independence in the entire table. Empirical 
Bayes estimators would be suitable since, as mentioned, they have smaller overall 
risks than MLEs. However, in the present context, this is not particularly useful 
when producing single cell estimates in very large contingency tables. 
In practice (as shown in section 3.4), there is very little difference among all 
these methods and very careful follow-up work is required to validate the signals, 
van Puijenbroek et al. (2002) accounted that "The heterogeneity of the data collected 
in databases of spontaneous reporting systems and the variety of biases influencing 
data (such as under-reporting) are likely to have more influence on the potential for 
signal detection than the small behavioural differences among the measures detected 
in this study". Because of this, one of the main priorities of any signal detection 
process is to reduce the number of false positive signals. There is an inherent danger 
in producing single cell estimates, which is that the data is not particularly reliable, 
resulting inevitably in many false positive signals. We can thus venture an opinion 
that the deficiencies of the present methods arise not so much due to the methods 
themselves, but more as a result of the general approach. Along the same lines 
we can say that significant improvement will not be obtained by refinement of the 
methods described in this chapter, but rather from alternative approaches which we 
will subsequently describe. 
We now take a moment to discuss the issue of validation. There are various 
ways to perform validation, the most common being to check the resulting signals 
with pharmaceutical experts. However, in the course of this thesis it has proven 
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difficult to obtain such validation, mainly due to the fact that it is often sensitive to 
obtain information pertaining to the side effects of certain drugs. In an alternative 
approach, one can ask for a data set with known signals to be able to check the 
efficacy of detection. This involves some significant resources, however, and have 
been difficult to obtain. 
3.6 Other Issues 
Many problems with the current methodology have been raised in certain sources, 
although the literature is very restricted with regard to the evaluation of the methods 
and suggestions for possible improvements. Most of the points being made seem to 
be concerned with the fact that there is very little knowledge of the performance 
assessment and comparison of the current methods. In particular, there is very little 
known about the behaviour of these methods when data issues complicate matters. 
We list some of the suggested issues below: 
• There is no established literature about the false signal generation rate (as 
mentioned, this poses a major drain on resources) of each method. The per-
formance of either of the methods described in section 3.3 in terms of gener-
ating false positive signals is not known. It is suspected and many practices 
feel that both methods do tend to generate a large number of false positives. 
One of the difficulties in this aspect is the precise meaning of a false positive 
signal. In real world data sets it is often the case that very severe ADEs need 
to be considered regardless of the signals generated and in this case these is 
no such thing as a false positive signal. That said, however, there is a genuine 
need to carry out well designed simulations to study the effects of false signal 
generation. The analyses currently being performed on real data sets can only 
be verified through previously analysed (independently) ADEs. 
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• There is no real effort made to assess the effects of other factors and variables. 
Although stratification is possible in these methods, it is currently not suf-
ficient to account for each patient profile. Additionally the effects of higher 
order interactions are not well catered for and httle is understood about this 
case. Whilst higher order associations (in particular drug-drug interactions) 
can be analysed using the current methods, the analyses are rather rudimen-
tary and at best extend to higher order counts. More needs to be studied in 
terms of the functionality of these methods for the aforementioned scenarios. 
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Chapter 4 
Alternative Approaches 
As we have discussed in section 3.5, there are many problems associated with the 
existing methods of signal detection in Pharmacovigilance. In this chapter we in-
troduce a new approach to detecting signals. We discuss the motivation behind the 
new approach, and the steps needed to arrive at practical conclusions. 
4.1 Motivat ion 
Underlying the new approach is the need to give the data some structure. At the 
outset, we have a categorical contingency table of raw counts. The present methods 
all involve detecting anomalously high counts within the raw table. However, given 
that this is a table of drugs against ADEs, it would be natural to ask whether 
some of the ADEs and drugs are closely related to each other. The obvious way 
to obtain such information would be through expert medical knowledge. However, 
this is by no means an easy task when one has tens of thousands of such drugs 
and ADEs. Such a task would comprise a large project in itself and may take 
years for its completion. The standard medical dictionaries only class ADEs and 
drugs according to the convenience of classifying terms and not according to their 
characteristics. This is not particularly useful for the purposes of research. Given 
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the lack of such an appropriate dictionary, we switch focus to an analytical approach 
to derive associations. 
4.2 Improvements 
How can we improve on the past methods if we have sets of strongly associated 
drugs and ADEs? Firstly, it must be noted that it is interesting in itself to have a 
classification of drugs and ADEs, and to compare the classes derived analytically to 
those from an external source (expert knowledge or even chemical information). For 
instance, one can break down a drug chemically and study it in terms of reactions 
it would cause due to its components. A comparison of this with its real world 
effects would be extremely useful in areas such as drug development. Moreover a 
classification would also allow many other tasks to be performed which are related 
to the concepts of similarity among drugs and ADEs. We will describe these later 
in this chapter. 
In terms of anomaly detection, the first logical step is to analyze the reduced 
contingency table, with classes of drugs and ADEs instead of the original individual 
drugs and ADEs. This would effectively pool the raw counts and reduce the problems 
associated with sample variation at low counts. Additionally this would allow us 
to analyse the pooled classes of drugs and ADEs in blocks and we can look for 
anomalies within these blocks. Secondly, we can still analyze the individual drugs 
and ADEs, but use the pooled information in the baseline instead. Again this would 
reduce sample variation, which is most severe in the baseline information and also 
we would be able to look for individual drug or ADE against the pooled baseline. 
And lastly, we can derive an alternative representation to that of a categorical 
contingency table, a spatial map of drug and ADE combinations for instance, with 
which we can apply more sophisticated models. 
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In effect, the improvements all center on the fact that we are no longer treating 
each cell in the original contingency table as a single entity, but we seek to gain 
knowledge of the inherent structure present in data. The aim is then to use this 
structural knowledge to incorporate into more sophisticated methods of anomaly 
detection than the smoothing methods. This structural information will be repre-
sented by similarities (distances) among drugs and ADEs and with these similarities 
we can pick out groups which are close together for the purposes of analysis. We are 
then no longer restricted to performing anomaly detection on single entities (which 
will always suffer from the effects of sampling variation and poor quality data, re-
gardless of the amount of smoothing or method or estimation), but we can apply a 
much more global perspective. 
4.3 Profil ing and Exper t Knowledge 
The analytical approach, which we will describe in depth in the next chapter, mainly 
focuses on how a drug reacts to different ADEs, and vice versa. In this way, we can 
think of the counts of ADEs arising according to a drug as a profile of that drug. 
Given only a raw contingency table, this is the simplest and most intuitive approach 
to deriving associations among drugs and ADEs. The expert knowledge can come 
from two separate sources. One can simply ask a medical expert to classify the 
drugs and ADEs according to similarities in practice and obtain a distance matrix 
this way. However, as mentioned, this is time consuming and infeasible for large 
numbers of drugs and ADEs (or, in the cases of new drugs and ADEs, one may 
know very little about them). Alternatively, but only in the case of drugs, one can 
obtain the chemical structures. This, on the other hand, has the disadvantage of 
not necessarily giving the right information (one can never be sure what the overall 
effect of a combination of chemical components is). 
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4.4 Out l ine of Remainder of Thesis 
Below we give a flow diagram of the general outhne of the work in the remainder of 
this thesis. 
Raw Data 
Matrix 
Dumouchel's Method 
Smoothed 
Data 
Matrix 
Chi-Squared 
Distance 
Matrix 
(ADEs) 
Distance 
Matrix 
(Drugs) 
Anomaly 
Detection 
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Data 
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Bayes Factor 
ICullback-Liebler 
Other 
Distance 
Matrices 
(Chemical) 
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(Drugs and 
ADEs) 
Anomaly 
Detection 
Figure 4.1: Flow Diagram of Remainder of Thesis 
To start with, we have the table with the raw cell counts. We can use a variety 
of methods (such as DuMouchel's GPS method) to smooth the raw counts so as 
to obtain a table of smoothed counts. From the smoothed data distances are then 
produced between drugs and ADEs. We will describe in detail in the next chapter 
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how to calculate these distances and in particular, the suitability of a variety of 
distance metrics. With the distance matrices in place, we are ready then to perform 
anomaly detection with the aid of data mining tools. In particular, we will introduce 
a new data mining tool which will allow us to detect peaks of drugs and ADEs 
given the distances between them. Additionally we have the idea of using external 
information, the already mentioned chemical information which we can organise 
into a distance matrix among drugs and other similar types of distances matrices. 
We will then incorporate these external distances alongside of the existing distance 
matrices we obtained using analytical methods. The combination of these disparate 
distances presents quite a challenge and we will devote further analysis to the most 
suitable method of achieving this. 
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Chapter 5 
Profiling 
In this chapter we describe the ideas of profihng a drug or an ADE such that we can 
measure the similarities among drugs and ADEs. We will describe the basic ideas 
of the profiling approach and discuss the various considerations we need to take 
into account. We will then describe and compare a variety of distance metrics for 
the purposes of measuring the similarities in our particular type of data. Keeping 
in mind the properties of our data we need to carefully choose a suitable distance 
metric. We apply these distances to both simulated and real data sets to compare the 
behaviour of these metrics. In particular we will be concerned with the behaviour 
of the various distances under the condition of sparsely populated data in high-
dimensional space. In general, such sparsely populated data sets require specifically 
designed distances and in certain instances fractional distances can be helpful for 
such purposes. We will discuss this further later in the chapter. 
5.1 Basics 
As discussed in section 4.3, the basic idea is that pairs of drugs can have inherent 
similarities and that we can estimate these similarities in a variety of ways (in 
terms of chemical similarities or, if that is not available, profiles of ADEs for each 
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drug). However, there are problems associated with generating distances between 
raw counts. The data itself is unreliable and contains a larger number of false 
reports; this can be very misleading in a low count profile. Together with the large 
sampling variation at low counts, one tends to obtain some rather arbitrary profiles 
and consequently distances. The following section discusses this in more detail. 
5.2 Uncer ta in ty 
If we are working with the raw counts, problems arise due to the differing sample 
sizes in the profiles. This is a problem which is not fully addressed in the present 
literature. The standard method of getting around this difficulty is by some form 
of standardising. Even after careful standardization, however, it is possible for 
anomalous cases to arise. Consider the example in Table 5.1, how can we obtain an 
accurate measure of the distance between these three vectors? 
Vector 1 Vector 2 Vector 3 
0 50 3 
0 50 2 
1 50 300 
0 100 5 
Table 5.1: Three Vectors 
Any way of standardising would give vector 1 as closer to vector 3 than vector 2. 
However, there is no real evidence to suggest that this should be true, since there is 
essentially very little information contained in vector 1. Testing procedures of the 
equality of these vectors would advocate that vector 1 has too small a sample size. 
However, as discussed, the low count profiles tend to be the ones we are interested 
in and we need some way of generating a distance. 
In order to fully eradicate all anomalous cases, we need some way of smoothing 
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the data so that sampling variation is reduced (in particular for low sample sizes). 
It is with this in mind that the approaches in the following sections are adapted. 
5.3 DuMouchel ' s Approach 
DuMouchel advocated clustering the ADEs according to their drug profiles, so as to 
obtain a reduced set of ADEs to work with instead of the MedDRA hierarchy. 
To obtain a set of distances for clustering, he first smoothed the table using GPS, 
and then calculated distances according to these smoothed odds ratios, in the same 
way as the profiling approach described already. We will discuss this method further 
in the subsequent sections. 
5.4 Dis tance Metr ic 
A metric d{ ) has to satisfy the following properties: 
1. Identity d{x,x) = 0. 
2. Symmetry d{x,y) = d{y,x). 
3. Triangular Inequality d{x, y) + d{y, z) > d{x, z). 
We now give some of the most commonly used distance metrics that can be applied, 
as well as one which has not appeared in the literature. 
5.4.1 Euclidean Distance 
One of the simplest L2 metrics is the Euclidean distance, defined by 
IT) = - tk)'- (5.1) 
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In our Multinomial-Dirichlet formulation, we can calculate the Euclidean distance 
between posterior estimates of so that we have 
d{Pi, Pi) = (5.2) 
The Euclidean distance obeys all metric properties. 
5.4.2 Distance 
In our problem, we use the posterior estimates of % , through which we can 
calculate two forms of the distance. 
The first is the well-known test statistic for independence. For two Multino-
mial vectors. Pi and fg, the test has the null hypothesis iJo : Pi = fg and uses the 
statistic 
r = (5.3) 
where Uij = Npij and = Npi.p.j. The second is the distance, defined by 
The two distances are equivalent, so we will only use the test statistic in the 
subsequent sections. 
The distance obeys all metric properties. 
5.4.3 Jensen-Shannon Divergence 
We use a symmetric form of the Kullback Liebler divergence, known as the Jensen-
Shannon Divergence (Lamberti & Majtey (2003)), to calculate the divergence be-
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tween the two distributions, f{9) and g{9), 
d{f{&),g{Q)) = fln^6d + Jg\nj69). (5.5) 
In our particular application, where / and g are the posterior distributions of two 
Multinomial probability vectors, so that / ~ Dir{fii + nu) and g ~ Dir{fii + 
the Jensen-Shannon divergence takes the form 
d{f,9) = ^ ( I n r ( ^ a i ) - ^ l n r ( a ^ ) + (5.6) 
i i i i 
- l n r ( J ^ Q ! i ) + ^ l n r ( Q ; i ) -
i i i i 
- i ( t a r ( 5 3 f t ) - ^ i n r ( f t ) + - i ) ( $ ( f t ) - •iiY.m 
i i i i 
- b r g A ) + J ] i n r ( f t ) - ^ ( A - i ) (»{f t ) - « E f t ) ) ) , 
i i i i 
where a , = yUj + riu and Pi = iJ,i + n2i. 
The Jensen-Shannon divergence obeys all metric properties. 
5.4.4 Bayes Factor 
The Bayes Factor does not appear in the literature as a distance measure^. This is 
strange since it is an intuitive measure of the similarity of two attribute vectors. 
We define our distance between two Multinomial probability vectors Pi and P2 
as the Bayes Factor when testing the null hypothesis Hq \ Pi = P2. Let D{x,y) be 
the distance between x and y. The Bayes Factor is calculated as follows. 
We take independent Dirichlet prior distributions for the Pi's under the alterna-
^For literature on the Bayes Factor see Kass & Raftery (1995), Kass (1993) and Gunel & Dickey 
(1974). 
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tive hypothesis f f i , so that 
Pi\Hirsj Dir{ai), 
then 
Pi\Hi, D ~ Dir{ai + rii). 
We can then calculate the Bayes Factor from the definition 
sn{d\e)^{e\h<,)d(> .... 
!tt(d\e)'k[e\h^)de' ^ ' 
eventually arriving at the analytical form 
BF — + Oiij — + aij) — (5.8) 
+aij)){n2j + 0=2; — l)(^(?i2j + a2j) — 
+a2j)){nij + aij — l){^{n2j + a2j) — 
+a2j)){n2j + a2j — l ) (^ (ny + ay ) - ^ ' ( ^ ( n y 
+Q;y))}-
Clearly the Bayes Factor does obey the Symmetry property. The Bayes Factor 
does not obey the Identity property, but this can be remedied easily by setting 
5.4.5 Comparisons of Distances 
First of all we would like to discuss some points concerning distance metrics. There 
are a wide variety of methods used in the data mining context associated with prob-
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lems such as clustering and nearest neighbour search^. In most instances suitable 
distance metrics are key to the performance of these methods. This can be partic-
ularly difficult when we are concerned with certain problems of the data such as 
sparseness and high dimensionahty. It can be quite difficult to generate meaningful 
distances under these conditions (we will discuss more on this later). For the re-
mainder of this section we will keep these considerations in mind when comparing 
the various distances that we can utilise. 
As discussed, an alternative notion of generating a distance between two Multi-
nomial vectors is that of testing the equality of two Multinomial vectors. The most 
commonly used statistic is the test statistic, given in section 5.4.2. The test 
has been extensively studied, such as in Cressie & Read (1984), Read (1984) and 
Tate & Hye (1973). This has been well studies in terms of power calculations and 
other criterion, with various minimum expectations suggested (Fisher et al. (1994) 
recommended 5, Kendall (1952) suggested 20). Improvements have been sought in 
using the general family of power divergence statistics, of the form 
- 1]' (5 9) 
A(A + 1 ) ^ ' ' 'E , 
with a smaller value for A suggested for small sample inference. The expectations we 
have in the present context are much smaller than would be involved in traditional 
tests, so that no modification is sufficient to provide a reliable test statistic. 
In the same way the Bayes Factor is derived from testing equality of two Multi-
nomial vectors. It is severely inflated by a fiat prior and is unreliable as a test 
statistic. Conversely, since it is a probablistic statement in favour of the alternative 
hypothesis, it takes into account the uncertainty present in the data. 
The Jensen-Shannon Divergence is a symmetrized and smoothed extension of 
^Mostly in specialised fields, for examples see Cheng et al. (2004), Huang (1998) and Pekalska 
et al. (2001). 
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the Kullback-Liebler Divergence (Menendez et al. (1997), Morales et al. (1994) and 
Lamberti & Majtey (2003)), which also belongs to a wider class of information-
theoretic based divergence measures. It is a natural measure of the divergence of two 
probability distributions. However, as with all information-theoretic measures, it 
gives the same distance to large objects that differ by a small amount as small objects 
that differ by the same amount. This stems from the fact that all information-
theoretic measures are based on the idea of the amount of information required to 
tranform one object to another. Clearly this deficiency can be distorting in the 
present context. 
The suitability of a statistic in a testing procedure is very different from its 
suitability as a distance metric. We are no longer concerned with the asymtotic 
property of a test, but rather the monotonic nature of a distance. To this aim we 
devise the following criterion, which is that a distance should obey the following 
ordering when applied to two profiles. If we have simulated Multinomial vectors 
under two Multinomial distributions, the intuitive ordering of distances should be 
as shown in Table 5.2 (from 1 — 6, with 1 being the smallest in orders). 
Ml (high) Ml (low) M2(high) M2(low) 
Ml (high) 1 3 6 5 
Ml (low) 3 2 5 4 
M2(high) 6 5 1 3 
M2(low) 5 4 3 2 
Table 5.2: Ordering of Distances (Ml(high) denotes vectors of high counts gener-
ated under Multinomial distribution 1, etc.) 
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5.5 Mul t inomial Formulat ion 
5.5.1 Method 
We have demonstrated some of the problems associated with the approach outlined 
in section 5.1. One improvement we can make is to take into account variations in 
the profiles and to smooth over these variations. 
As noted in section 5.3, DuMouchel uses a smoothing approach to produce a 
distance. He produces a measure for each cell using the Gamma-Poisson Shrinker 
and defines profiles of drugs and ADEs using these measures. This does indeed 
smooth over some of the variation in the profiles. 
Our approach uses the raw counts to produce our distance metric, rather than 
a derived measure which seems to be rather ad hoc. On the one hand, we approach 
the problem from a statistically intuitive way. On the other, we believe that we can 
much better outline the requirements of our distance metric and make improvements 
where necessary. 
We assume that each profile follows a Multinomial distribution, so that 
p{xi,...,xn\pi,.--,pn)= [ ^ (5.10) 
k 3/2 . . . 
where x^. . .Xn and p i . . .pn denote cell counts and parameters in a single profile, 
and N is the sum of the profile. 
We can estimate the distribution through maximum likelihood, and we would 
obtain the ma^dmum likelihood estimates 
Pi = (6.11) 
Clearly the estimates are affected by sample size, and at low counts are unreliable. 
One way to get around this is to take a Bayesian approach to the problem, by 
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assuming a prior for the Multinomial likelihood. We can use the conjugate prior to 
the Multinomial distribution, which is the Dirichlet distribution, such that 
P(Pl, • • • • • • , /"n) = (5.12) 
The posterior is also a Dirichlet distribution, of the form 
pipl} • • • ipnl'jly • • • 1 Tnj ^1) • • • ) ^n) — ( " 3 ) 
In the absence of prior knowledge, we can simply use a uniform prior. However, 
in some cases we would have some prior knowledge, and the prior parameters can 
be set according to our prior knowledge and in such a way that strong information 
in the data is needed to significantly change the shape of the distribution in the 
posterior. This would then be an intuitive way of smoothing over the data to obtain 
a posterior distribution. 
The above approach already has one major advantage over using a derived mea-
sure; the ability to incorporate prior behef into our distance metric. Another intu-
itive way of specifying the prior is to give greater weight to the more severe ADEs, 
and this can be achieved by setting a weaker prior parameter for the ADE so that 
the posterior is affected more sharply by the information in the data. 
Once we have the posterior distributions for the profiles, we can then obtain a 
distance metric based on the posteriors. The Kullbeck-Liebler distance is one natural 
metric, as it measures the discrepancy between two distributions. Alternatively, 
since we have the distributions of the profiles, we can construct a distribution of 
the distance between two profiles. This would have the advantage of modelling the 
uncertainty of distances between profiles. 
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5.5.2 Prior Specification 
We will now discuss how we should specify the prior in our Multinomial distribution. 
Although we have discussed the use of a uniform prior, this is not particularly 
applicable in this case. Clearly we need to attach different prior parameters to 
different parameters in the likelihood to reflect the differing basehne information. 
One approach we can take is to assign the prior parameters as the means of respective 
ADEs across all drugs. This would have the effect that the shape of the posterior 
is changed according to a combination of differing baselines and observed counts. 
Alternatively, we can assign a uniform prior, but allocate differing weights to the 
counts for each ADE. This would have the effect that the shape of the posterior 
would change at the same scale of magnitude. Again these weights can be decided 
according to baseline information. 
The above approaches to prior specification depend on a combination of subjec-
tive assessment by the analyst and information in the data. An alternative is to 
use an entirely data-dependent method such as Empirical Bayes. We prefer, in this 
instance, to use more subjective priors, since we can specify clearly what we require. 
5.5.3 Distance 
As already mentioned, one distance metric we can use is the Kullback-Liebler dis-
tance between distributions, which is of the form 
KLD{q\p) = j log{^)p. (5.14) 
For two Dirichlet densities p and q such that 
- ,/4.) = 
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q{Pl, • • • ,Pn|Ai, . . . , A„) = \ 
the Kullback-Liebler distance is then 
KLD{g\p) = - l i ( E f t ) ) ) - (5-15) 
Note that the Kullback-Liebler distance as given above is of the form q given p 
and is not the same as KLD{p\q). Thus the Kullback-Liebler distance is not sym-
metric. The Kullback-Liebler distance also does not obey the Triangular Inequality, 
so that only one of the three properties of a metric is satisfied {KLD{p\p) = 0). 
While non-symmetry is a problem, the disobediance to the Triangular Inequality 
is particularly undesirable when we need to look for clusters in high dimensional 
space. This renders the Kullback-Liebler unsuitable to our purposes. To illustrate 
the above, we have plotted 4 distribution functions of the Beta{a, (3) distribution, 
which is a 2-parameter Dirichlet distribution. 
I I I I I I I I I I I I I I I 
^4 ^6 1 
Figure 5.1: Plots of Four Beta Distributions 
In Figure 5.1 the distribution plotted in black is Beta{5,45), which we will take as 
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our prior distribution. The distributions plotted in green and blue are Beta{10,90) 
and Beta(15,135) respectively and that plotted in red is Beta(13,47). Clearly we 
can see that there is a large difference between Beta{13,A7) and the other three 
distributions while there is a small difference between those three distributions. 
This is to be expected, simply by a calculation of the mean and variance of the 
distributions. As such we would expect this to be reflected in our distance metric 
between the distributions. Table 5.3 shows the Kullback-Liebler distances between 
these distributions. 
Beta{b, 45) Beta{10,90) Beto(15,135) Beta{13,47) 
Beta{5,45) 0 0.47 3.86 
Beta(10, 90) 0.10 0 OIK 3.58 
Beta(15,135) 0.22 0.04 0 3.57 
Be(a(13,47) 2.55 4.83 7.27 0 
Table 5.3: Kullback-Liebler Distances Between Four Distributions 
As we can see from the last row, these distances are inflated and do not obey 
the Triangular Inequality. We can note at this point that the Kullback-Liebler 
distance is generally used in the literature to give an idea of the discrepancy of two 
distributions and, as we have argued, is clearly not suitable if we then proceed to 
work implicitly with these distances. 
As we can see from Figure 5.1, an alternative, natural distance to use would 
be the overlapping regions under two Beta distributions. However, to extend this 
to high dimensions would be difficult to evaluate and almost certainly computer 
intensive. One way to do this would be to sample points under the two distributions 
and thus sample the percentage of points that fall under both distributions, which we 
can then use as the distance metric. However, while this is applicable to distributions 
of two parameters such as the Beta or Normal distributions, in higher dimensions 
there is no straightforward analogy of such overlapping regions (indeed we can no 
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longer visualize exactly what overlapping regions mean). 
Another approach to take would be to either work with the posterior Dirichlet 
parameters or a scaled version. If we scale them by summing them to unity, then 
we are simply using the posterior estimates of the likelihood parameters. Again in 
this case we can use forms of the Euclidean or distances between the posterior 
parameters or estimators to evaluate a distance. 
5.5.4 Application 
Here we describe the simulated dataset of section 5.6. We will have a prior based on 
the mean. Subsequently we will use a distance between the posterior estimates 
of individual likelihood parameters. 
If we use the raw means for the prior, we will find that some of the means are 
very small, which is then equivalent to using a weakly informative prior. We need to 
use a stronger prior so that strong data is needed to change the posterior, therefore 
we will make the following initial modifications to the prior, shown in Table 5.4. 
Mean Prior Parameter 
< 1 mean + 1 
1 - 2 mean + 2 
2 - 1 0 mean + 3 
10+ mean + 5 
Table 5.4: Prior Specification Based on the Mean 
We can see from Figure 5.2 that we have now a fan shaped effect in our distances. 
Prom Figure 5.2(b) and 5.2(c), we can see that the profiles with low counts are now 
clustered together and the counts increase in an outward direction from the lowest 
counts. In effect, low counts provide no real information and thus do not change 
the posterior parameters very much. This has achieved one of aims of our distance 
metric, in that uncertainty is incorporated. However, we now have a clear separation 
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Figure 5.2: Plots of 1st v 2nd Principal Component of Distance Matrix Obtained 
by Multinomial Approach 
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between profiles with low counts and profiles with high counts. This is clearly not 
entirely desirable. Whilst we would like to have this separation to a degree, we also 
need our distance metric to take into account the profile distributions. This above 
analysis shows an opposite effect to the basic profihng method discussed earlier. We 
have now a condensed region of low counts, which are now close in distance, and the 
distances tend to increase with increasing count values. Looking at Figure 5.2(d), 
we can see a very clear trend of the simulated data points from low counts near the 
central condensed region to high counts. We need to take this into consideration 
when applying the distances to real data. 
5.6 Applicat ion and Discussion 
In this section we apply all the above methods to a set of simulated data. The data 
comprises of 70 drugs and 2245 ADEs. The reason for simulating such a data set is 
that we wish to investigate the behaviour of the distance metrics when applied to 
a data set closely mirroring that of real world data. We also wish to differentiate 
easily amongst the distances, hence we will only simulate 70 drugs so as to be able 
to easily interpret the results. We will apply our methods to the drug profiles. The 
70 drug profiles are simulated from 3 distinct Multinomial distributions (this is done 
for convenience due to the fact that it is difficult to simulate an adequate data set 
from Poisson distributions that closely resemble real world data), of sizes 20, 30 and 
20. Within each group of simulated data, we change the sample sizes from very low 
(50 counts in 2245 ADEs) to high (100,000 counts in 2245 ADEs). 
The methods we will use are: 
1. DuMouchel's method, with distance 
2. Multinomial-Dirichlet formulation, with distances: 
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• Kullback-Liebler distance 
• distance 
• Bayes Factor 
We use hierarchical cluster analysis to demonstrate whether the distances obey 
the ordering in Table 5.2. We can see from Figure B.l to B.8 (Appendix B) that 
DuMouchel's method performs the best with complete-link clustering, also note the 
similarities between the B.3 and B.5 and between B.4 and B.6 as these two distances 
perform similarly for the particular data we analyse. In fact, all the methods apart 
from the Bayes Factor perform much better with complete-link than single-link, 
whereas for the Bayes Factor this trend is reversed. The reason is that for all other 
distances apart from the Bayes Factor, two profiles with low counts are closer in 
distance than two profiles with large counts from the same group. Thus single-link 
clustering would perform poorly as low profiles from all groups would cluster first, 
followed by higher profiles, leading to arbitrary clustering. For the Bayes Factor this 
is not so, thereby leading to better single-link clustering. It is difficult, however, to 
infer more useful information regarding the performances of the distances from the 
clustering alone. We will also mention that the performance of the Bayes factor in 
terms of separating the simulated Multinomial distributions is superior to the other 
distance metrics. 
The results show that the only distance capable of fulfilling the criteria of Table 
5.2 is the Bayes Factor. One would intuitively expect the method by DuMouchel of 
comparing smoothed odds ratios not to follow the above ordering. In particular, at 
low counts, one will simply have many of the smoothed odds ratios being the same for 
two different profiles due to the fact that they are dominated by the prior smoothing 
parameters. This leads to low counts being very close to each other, regardless of the 
distance used (any L2 norms, for instance). The Euchdean distance clearly suffers 
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from the same problem of having low counts close to one another, due to the lack 
of normalization. The Jensen-Shannon divergence has the problem of giving two 
distributions as being closer to one another if there is a large proportional change in 
small parameter values, as opposed to a small proportional change in large parameter 
values. The distance is not appropriate for small expected values of cell counts, 
and distorts the distances for such values to be smaller than the weight of evidence 
suggests. The Bayes Factor, on the other hand, does obey the ordering in Table 
5.2, since it is a probabilistic statement in favour of the alternative hypothesis of 
inequality of Multinomial vectors. It should take into account the sample sizes of the 
vectors (in other words, the uncertainty of making such a probabilistic statement). 
Finally, it should be remarked that, of the ordering in Table 5.2, the focus of the 
previous analysis has been on the ordering numbers 1 and 2. This is not negligence, 
but all other orderings are rather obvious and one would expect any distance to 
demonstrate such behaviour. Of the ordering numbers 1 and 2, we can of course force 
any distance to follow this order by normalizing with a size factor. Indeed, it has 
been suggested that this should be performed on information-theoretic divergence 
measures due to their deficiencies as discussed in section 5.4.5. The simplest such 
device is to normalize each distance by the sum of counts in the two profiles, 
where N{Pri) is the total count in profile 1. However, such normalization destroys 
other inherent orders in the distance metric. For instance, if we have the following 
vectors, normalization can easily give vectors 3 and 4 being closer than vectors 1 
and 2, an undesirable situation. 
In the next analysis we have simulated a dataset of 20 drug profiles under three 
different Multinomial distributions. We then insert this simulated dataset into a 
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Vector 1 Vector 2 Vector 3 Vector 4 
0 0 50 3 
0 0 50 2 
10 20 50 300 
0 0 100 5 
Table 5.5: Four Vectors 
real dataset of 152 drug profiles. In each profile there are 2245 ADEs. The aim is to 
see how well the profiling method separates the simulated groups from the real noisy 
data. In the simulated dataset, the marginal counts of each profile range from low 
to high (50 to 10,000), which will give us an idea of the performance of the profiling 
method for differing counts. 
We calculate our distance metric using the Euclidean distance, after standard-
izing by summing each profile to unity. We then apply Multidimensional Scaling 
(MDS) to the resulting distances and plot the first two components against each 
other for the purposes of visual inspection. 
In Figure 5.3(b), we can see the separation of the different groups. It can be 
seen that the groups have a high degree of overlap, which is not desirable since we 
would expect more distinct groups. The distinct groups which do arise are profiles 
with high counts. The simulated profiles with lower counts, on the other hand, are 
not picked out at all well. 
It is also interesting to note that the simulated profiles cluster together, regardless 
of which groups they belong to. This can be seen clearly from both Figure 5.3(a) 
and 5.3(b). We believe this is due to the fact that the simulated profiles have a 
much more regular structure, whereas real datasets tend to be much more noisy and 
irregular. , 
From Figure 5.3(a), we can see the general structure of the profiles. The elon-
gated shape is a little worrying, since we should expect a more spherical shape, 
although we can see that the vast majority of the profiles are clustered in a small 
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Figure 5.3: Plots of 1st v 2nd Principal Component of Distance Matrix Obtained 
by Basic Profiling Method 
condensed region. This can be explained by Figure 5.3(c). We can see that the 
profiles represented by red dots are profiles that contain very few counts (those to 
the right only contain 1 or 2 counts). As such, they are essentially outliers. Indeed, 
if we were to plot all the components in high dimensional space, then these profiles 
with low counts would be much further away from each other. However, since these 
counts are so low, we really can not trust to this distance. Rather, we would ideally 
like these profiles to be closer together to reflect the fact that we can make no clear 
decision. 
It is worth noting at this point that the two dimensional MDS plot is simply a 
tool to enable us to visualize the distances. In reality, we would be working with 
the distances alone. Clusters which are close together in these plots are certainly 
not always close together in higher dimensions. 
As a result of the above analysis, we can gather that the basic profiling method 
has some undesirable properties. Firstly, it does not separate profiles well when 
counts are relatively low. Secondly, profiles with very low counts can be very far away 
from one another. This is clearly undesirable since we have insufficient information 
to draw such a conclusion. And finally, we have no indication of the uncertainty in 
the data. 
5.6.1 Conclusion 
In this chapter we have seen that the basic profiling method does not perform very 
well when profiles contain low counts. It is an interesting question to ask what 
we can do with these low counts. Some of the previous approaches have simply 
eradicated profiles with low counts. However, as we have argued, this is a dubious 
practice at best. What we need is some way of taking into account the uncertainty 
in the profiles and construct our distance metric to reflect this uncertainty. 
Finally we would like to discuss some traditional approaches in data mining. 
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There are a wide variety of methods used in the data mining context associated 
with problems such as clustering and nearest neighbour search. These are based on 
using some distance metric between points in high dimensional space. The problems 
associated with the curse of dimensionality are well known in this context. For 
instance, Aggarwal et al. (2001) and Beyer et al. (1999) gave accounts of data mining 
in high dimensional space. Some of the proposed solutions consist of data mining in 
subspaces and using modified distance metrics (Beyer et al. (1999)). However, we 
have in our problem a different formulation to the traditional approaches, which are 
mainly concerned with large data sets containing many observations with a large 
number of well defined and measurable attributes. One then proceeds to define 
distance metrics between attribute values and perform clustering. We have no such 
luxury, in that our attributes contain differing counts and therefore differing degrees 
of uncertainty. Our primary concern then is to define distance metrics which can 
take uncertainty into account. In this context there has been little work in the 
present literature, in particular there has been fittle discussion of a suitable distance 
metric to use. 
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Chapter 6 
Data Mining Software 
This chapter is a rather stand-alone chapter from the rest of the thesis. However 
data mining software plays an essential role in analysing the real data sets, therefore 
we feel it is apt to discuss the central issues in data mining software before going 
further. 
With the relatively recent explosion of data mining applications, so has a need 
for data mining software arisen. Corresponding to this there has been an explosion 
in the number of data mining packages marketed in recent years, to the extent 
that there are at present a bewildering amount of software available for both the 
commercial and academic users. These include some major packages which have 
been maintained over many years and are consequently very mature, some more 
recent packages as well as some very application specific packages. 
For many users, choosing a suitable package is not an easy choice. There has been 
very little in the literature to help facilitate such a decision (some useful comparisons 
can be found in Davi et al. (2003)), which can perhaps be explained by the fact that 
this is rather difficult to achieve and it is much more common to tailor a package to 
a user's specific requirements. In this chapter we will review some of the packages 
available and compare them according to a set of criteria we have devised. In 
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particular, we will be looking at the packages SPSS Clementine, Statistica, KXEN, 
Ghostminer and XLminer. While this is rather a small selection, we have made this 
choice so that there is a wide representation of the types of packages available. We 
will mention more on this in the remainder of this chapter. 
It must be stated here that the goal of this chapter is not to look in detail at 
the technical aspects of each package in terms of the types of analyses available, but 
rather to give a feel for the general issues that arise when using each package and 
to hopefully relate to the common users. To this end we will use some or all of the 
following list of criteria in the following sections; 
1. General features (including pricing, learning curve, user interface, output). 
2. Toolset. 
3. Advanced features (including customisation, exportability, database extrac-
tion). 
4. Balance between basic and expert users. 
5. Scalability. 
The rest of this chapter is organised in the following way. Section 6.1 gives a 
review of the capabilities of present-day software. Section 6.2 compares the pros 
and cons of the various packages. Some relevant examples are given in section 6.3. 
6.1 Features of a Modern Da ta Mining Package 
In this section, we will describe some of the aspects of a modern data mining package. 
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6.1.1 User Interface 
There are generally three types of user interfaces for a standard package, a menu 
based approach, a stream based approach and scripting. The menu approach is 
generally for the more basic users. The stream based approach is slightly more 
advanced in that more care must be taken in deciding on the connection of nodes. 
Streams have two key advantages over the menu options. They allow complicated 
streams to be saved as projects and there is a clear sense of separating parts of a 
larger project into smaller manageable sub-projects. At the most advanced level, one 
can script for user customisation. Figure 6.1 shows the workspace for the Statistica 
package. 
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Figure 6.1; Workspace for the Statistica Package 
We see the typical elements of a workspace, a drop-down menu of options and 
a spreadsheet for manual data input. At the bottom of Figure 6.1 we can see the 
stream interface. Figure 6.2 shows in more detail the stream workspace of the Statis-
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tica package. Statistica takes the approach of forcing the user to create a stream of 
four separate parts, in order to maintain a clear and manageable appearance. This 
is not true of other packages such as Clementine. On the other hand, complicated 
streams can be confusing when links point back and forth and it can be visually 
clearer to keep streams pointing in a single direction. 
Jafii: 
F igure 6.2: Stream Workspace for the Statistica Package 
6.1.2 Toolset 
In this section we list some of the common data mining tools available today. It 
must be noted that a comprehensive coverage of tools does not necessarily make for 
a good package. As is often the case, packages that can perform a specific set of tasks 
well may be preferable to the more general packages in terms of speed and accuracy. 
Moreover, it can be important to limit applications for the novice users who can be 
confused by a vast array of analytical tools and options. Choosing an appropriate 
method of analysis can often be difficult without the necessary statistical training 
and often the best option is to fully automate the modelling process to provide quick 
and easy solutions. 
Table 6.1 summarises the types of analyses available in each of the packages. 
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Statistica Ghostminer Clementine KXEN XL 
Data Cleaning/Manipulation y y y y y 
Missing Data Imputation y y y y 
Generalised Linear Models y y y y 
Multivariate Analysis y y y y 
Principal Components Analysis y y y 
Factor Analysis y y 
Canonical Analysis y y 
Multidimensional Scaling y y 
Nearest Neighbour y y y y y 
Correspondence Analysis y y 
Discriminant Analysis y y y 
Classification y y y y y 
CART y y y y y 
FSM y 
kNN y y y y y 
SSV l^ee y 
Committee y y y 
Neural Networks y y y 
Multilayer Perceptrons y y y 
Kohonen y 
Radial Basis Functions y y y 
Time Series Analysis y y y 
Cluster Analysis y y y y y 
Association Rules y y y y 
CHAID Models y 
Random Forest Models .y 
M A R Splines y 
Support Vector Machines y y y 
Table 6.1: Summary of Available Analyses 
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6.1.3 Visualisation and Graphics 
Visualisation can often be the most effective way to start any analysis. Today's data 
mining packages often provide powerful graphical features to enable fully integrated 
support. In particular, many packages provide flexible graphical features which are 
fully customisable along with additional user-defined graphs. Graphs can also be 
dynamically linked to the data (even external remote data bases) to enable automatic 
redrawing and updating with real time data changes. 
Table 6.2 summarises the types of visualisation and graphical tools available in 
each of the packages. 
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Statistica Ghostminer Clementine KXEN XL 
Visualisation y y y y y 
Histograms / Bar Charts y y y y y 
Pie Charts y y y y y 
Box-Whisker Plots y y 
Scatter Plots y y 
Probabihty Plots y 
2D Graphs y 
Scatter Plots y y y y 
Range Plots y 
Quantile Plots y y 
Normal Probability Plots y 
Line Plots y y 
Sequential/Stacked Plots y 
3D Graphs 
Scatter Plots y y 
Bivariate Histograms y y 
Range Plots y y 
Surface Plots y y 
Contour Plots y y 
Ternary Plots y 
Categorized Plots y 
Smoothing Plots y 
Tessellation Plots y 
Matrix Plots y 
Lift Charts y 
Correlation Plots y 
Misclassification Plots y y y 
Table 6.2: Summary of Visualisation Tools 
6.1.4 Customisation 
Ultimately packages cannot provide the exact features that an advanced user is 
entirely satisfied with. The user can customise the modules to suit individual pref-
erences. Most packages provide easy to edit scripting features with each pre-defined 
module. Figure 6.3 shows this feature in Statistica, which uses industry standard 
Visual Basic as its scripting language. 
Of course, to customise code requires a certain degree of advanced understanding, 
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Figure 6.3: Customisation in Statistica 
but this is generally quite straightforward to learn. In particular, a nice feature of 
most data mining packages is that all menu based tools and options can be converted 
into script and this greatly facilitates the scripting procedure since command line 
scripts can simply consist of portions of existing scripts. 
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6.1.5 Database Extraction 
The scalabihty of modern day packages means that they can handle massive amounts 
of data. In most instances it is impossible to store the data on a local machine. 
Remote data warehouses are used to store the data source and any package must 
have the facility to access this data source. Mostly this is quite straightforward with 
in-built functionalities which allow easy access of compatible data sources. 
6.1.6 Deployment and Exporting 
Deployment refers to the use of an existing predictive model on a fresh set of data. 
Most packages have such a feature available. Moreover, models can be readily ex-
ported and deployed in other integrated applications. This can be done by either 
exporting the model itself to compatible applications or by converting the model to 
script and exporting the script. It is very important for a modern day package to 
be able to export its modules across to other packages. To this end a programming 
language, Predictive Model Markup Language (PMML), has been devised to enable 
universal compatibility among applications when defining statistical and data min-
ing models. This means that any particular package can convert its modules into 
PMML and subsequently run in another application. Most packages provide such a 
facility for several other languages such as Java, C + + and variants of Visual Basic. 
Figure 6.4 shows the exporting option in Statistica. 
99 
D.^B;4u,A itAK "1 ' #,*wdwwi' w«*« 
a+V'Tufato?. 
*v. 
#bmf |kw# 
i VW1 27^  
uasaw 
;*! IV«- jjM 
<)Mn *miw» 4*wi#*M* bf km* 
NHw Rw) w« ba: WMimi s»w*;w bwiMhw 
muiWw4#ki«!MM) AhWW&**(« iWM3 
*X&iNCl#*U*Kl* 
Km4#MiAAn^ ;W*nrhifi 
efn#*M#A"WWAUM;w# CfW&MWAwiWtyW* Af&Whmfl mwAi 
XWT&WaAkMfi * 
WaWlik 
, . 
W » W M n » W l 
&WIU»x#f IWwfli* 
#A6«W( 
y . .-phiaewil":; 
tWfMOM M — jWuM *M^I$W4l4) 
n"r% ^ ^ ^ «ut !* t,4MWbm M«*h lu 
»*k # ^  k) #*#* 
IW# Di#M#w#*^(k#h$li#WwwW I 
k#w#M 1-A# 
_ _ 1 ^ m -W_KL. 
a 
KirKMAidWL I IS* ai* *r,m jQwrnNm-hwu Vwuwv* 
Figure 6.4; Model and Script Exporting in Statistica 
6.2 Compar ison of Software 
6.2.1 Advantages and Disadvantages of Data Mining Pack-
ages 
Stat is t ica 
Statistica is a very complete package in terms of both the analyses that it can 
perform and the graphical tools available. As one can see from section 6.1, the 
data mining package contains a very extensive set of methods including some very 
specialised analyses (possibly more so than any other existing package today). It 
is also one of the very few packages that incorporates rich sets of both parametric 
statistics and data mining tasks. Each individual method contains a powerful set of 
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user definable features which cover most aspects of the method. Additionally it is 
highly flexible both in terms of user definable features and easy to use customisation 
of existing features. 
The user interface is easy to use and intuitive, with most aspects adjustable. On 
the other hand, there is a deliberate effort to simplify some of the features, especially 
for the stream nodes, in an attempt to avoid confusing users with overly complicated 
analysis options. These options can of course be customised through scripting. 
Scalability is impressive in Statistica, having the ability to handle large datasets 
and databases across different platforms. Indeed, it is one of the leading applications 
in terms of scalability. 
One of the nice features of Statistica is that it caters well for both the basic 
and advanced users, with a relatively straightforward learning curve but also very 
powerful customisable features for the advanced users. Indeed, one of the most 
important aspects of a universal data mining package is its ability to cater for users 
from all walks of life. 
The only problem which has arisen is the propensity for Statistica to crash oc-
casionally for rather arbitrary reasons. 
Statistica provides an academic license and is affordable for personal use. Sta-
tistica is possibly the most complete package available today. Clearly a great deal 
of care has been taken over this package and most aspects have been fine tuned. 
KXEN 
KXEN is a specialised package that implements the Support Vector Machine. It 
performs a limited set of methods which includes mainly classification and regression, 
but in this capacity it is extremely fast and accurate. The philosophy of KXEN is to 
deliver fast business solutions on vast amounts of data. It dispenses with providing 
the user with a variety of analytical tools in favour of one approach. The aim is to 
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provide a non-expert user with a fast and accurate model on large data sets. We say 
non-expert because KXEN does not provide a set of tools to choose from and the 
process of data analysis is fully automated once a clean data set is presented to the 
internal Consistent Coder (for data preparation). Because of the full automation 
of KXEN, no sophisticated user interface is employed for the front-end. Figure 6.5 
and 6.6 show two of the KXEN user interfaces. The user is asked initially to choose 
a model and input data, after which the whole analysis is carried out by simply 
clicking the Analyse button shown in Figure 6.6. 
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Figure 6.5: KXEN User Interface Figure 6.6: KXEN User Interface 
The output is again entirely automated and rather limited, and user defined 
graphics cannot be performed. For instance, in Regression/Classification, the out-
put is based on the performance indicators KI and KR which correspond to model 
consistency and robustness. Figure 6.7 and 6.8 show examples of model output that 
are available. 
In essence, KXEN is a nice tool that accomplishes well what it is designed to do, 
but it is rather limited. Its main use is to give a fast overview (consisting mainly of 
variable selection, event associations, data sufficiency and exploratory modelling) of 
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Figure 6.8: KXEN Lift Curves 
a large data set to the business user. It cannot perform several other key aspects 
of data mining such as data cleaning/manipulation, data visualisation, exploratory 
data analysis and other in-depth statistical analyses. 
Clement ine 
Clementine is a very mature package. This means that it is easily integrable within 
a work environment and has many third party vendors for complimentary features. 
Clementine contains an extensive set of data type and quality nodes and performs 
very powerful data checking and manipulation operations as well as missing data 
imputation. Additionally, powerful optimal parameter search routines are built into 
most of the data mining algorithms to enable fast computation. It contains an 
useful variety of algorithms which can be customised through its scripting language 
CLEM. On the downside, it has a limited range of graphical features. Its price is 
also prohibitive for personal and academic use. 
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Ghostminer 
Ghostminer is a package that concentrates extensively on classification methods. 
As such it has a substantial range of such algorithms. It is reasonably fast compu-
tationally for such purposes. However, this is to the exclusion of most other data 
mining techniques and it is therefore very restricted in the analyses it can perform. 
Given the rather restricted nature of its algorithms, it seems not to have any obvi-
ous advantages over other packages when it comes down to both the computational 
aspect and also the level of customisability. In terms of the graphical packages and 
data manipulation Ghostminer is also not outperforming its competitors. 
XLminer 
XLminer is a limited package in terms of the methods and features it contains. 
Because it is an Excel add-on, it contains many of the limitations of Excel, in 
particular scalability and very limited graphical tools. On the other hand it is very 
cheap and fits within the Excel package which most people already have. Whilst it 
cannot be expected to perform in-depth analysis, it contains a useful set of methods 
for the basic users to try their hands at performing some data mining tasks. In 
fact, it contains a very useful set of data mining applications which include most 
of the common types of analyses. More features are being developed to add to the 
existing package which should enhance its capabilities somewhat and these include 
database extraction, data manipulation tools and graphical enhancements. At its 
price, XLminer provides a nice package for the non-serious user. 
6.3 Examples 
In this section we will examine the performance of some packages when applied to an 
example data set. The data set we used is the ADULT data set, which is available 
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through the onhne UCI Data Repository. The data set contains 48842 cases with 
14 attributes which are split into 6 continuous and 8 nominal attributes. There are 
7% missing values in the data. 
In Statistica, we simply used a classification tree. The analysis took 3 minutes 
to complete. 
In KXEN, the analysis took a few seconds. The model output gives KR = 0.986 
and KI = 0.809. We show two of the most important output graphics in Figure 6.9 
and 6.10. 
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Figure 6.10: Variable Contribution 
in KXEN for Adult Data Set 
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Chapter 7 
Peaker 
In this chapter we discuss a pattern discovery tool called Peaker. Peaker is used to 
identify modes (or dense regions) in a data set. 
Mode-hunting (bump-hunting) has attracted little attention over the years. The 
problem, in its basic formulation, is to identify a set of modes (areas of high proba-
bility density) in the data. This of course is closely linked to the problem of density 
estimation. However, as opposed to estimation of the underlying density, detection 
and verification^ of a bump is more of a significance testing problem. The simplest 
way of detecting a bump is by computing the maxima of the density estimates. In 
this sense obtaining a good density estimate is critical to the detection of signifi-
cant bumps (for literature in this context see Good & Gaskins (1980)). In many 
contexts, the problem we are faced with can be related to that of outlier detection. 
Outlier detection is well established in statistics and there are many methods avail-
able which have sound underlying statistical properties. Moreover, in computational 
sciences there have also been many advances. We will note here, however, that one 
of differences is that we are more concerned with the properties and behaviour of 
any patterns that we find rather than the process of looking for them. In particu-
^These are known as pattern detection and pattern verification which we will describe later, 
discussions on these can be found in Hand & Bolton (2004). 
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lax, we look for the underlying mechanism that gives rise to a pattern rather than 
stopping at the detection and verification of an outlier. That said, there are many 
similarities and it is useful to keep this mind since many techniques have already 
been developed which can be useful as alternative approaches to the problem we try 
to solve. 
In the data mining context bump-hunting is more concerned with looking for 
localized modes in the sample space rather than the exact estimation of the under-
lying density. The existing methods approach the problem by looking for subregions 
with higher densities than the whole sample space (see Friedman & Fisher (1999) 
and Barnett (1976)). 
Peaker takes a different approach. It looks for data points (which we call peaks) 
at the location of which there is a higher estimated probability density than at 
neighbouring data points. In this respect it only looks for approximations of sample 
modes (points which are close to modes). Peaker has the advantage of being sim-
ple to compute, intuitively clear and easy to extend to higher-dimensional space^. 
However, we are faced with a new set of problems. In the first instance, we need to 
identify modes by other means to computing maxima^. Secondly, verification of a 
mode takes on a different perspective. The work in this chapter follows the earlier 
results presented in Adams et al. (2001) and Bolton et al. (2004), and follows closely 
the work presented in Zhang k Hand (2005) and Hand k Zhang (2005). 
7.1 M e t h o d 
The basic Peaker algorithm is as follows: Given a data set {xi, i = 1,... ,n) of some 
dimension d, we calculate the probability density estimates f{xi) at each point Xj. 
^Although it can be computationally expensive over a large data set with many observations. 
^We have no direct means of evaluating a maximum, since we are not evaluating the density 
surface. 
107 
For each point xi, we say that it is a peak with M{xi) = m iff f{xi) > f{xj), \ /xj £ 
Nm{xi) but f{xi) < where Nm{xi) is the set of the m nearest neighbours 
to Xi (defined by some distance function d{xi, Xj)) and is the (m+l ) t h nearest 
neighbour to Xj. Initially we call all points xp, for which M{xp) > 0, peaks. In the 
above, the distance function we will typically use is the Euclidean distance and the 
probability density estimates will be obtained via kernel methods. 
We will now also give an algorithmic outline of Peaker: 
1. Begin with the data set (xj, i = 1 , . . . , n). 
2. Calculate f{xi) for all Xj and store resultant values in vector FX[n]. 
3. For each point Xf. 
(a) Calculate distances from z, to all other points and store in vector DIST[n— 
!]• 
(b) Sort DIST[n — 1] in ascending order and store the resulting indices (of 
data points) in vector ORDER[n — 1]. 
(c) Look through ORDER[n — 1] and return M(xj). 
Note that in the above algorithm, we would already obtain the inter-point dis-
tances in step (2), which we could store for later usage in step (3a). However, this 
is not possible as sample size becomes larger, therefore we have to calculate the 
distances again. 
Peaker essentially estimates the pdf at each data point and performs nearest 
neighbour search on all data points, identifying those points which have a higher 
pdf estimate than their surrounding points (we will call these local peaks). Clearly 
peaks arise as a result of a local region of anomalously high concentration of data 
points. A local mode of the underlying true density will thus tend to lead to a 
108 
peak. We can thus regard peaks as approximations to local modes in the underlying 
true density. We say approximations since peaks a) derive from density estimates 
rather than the true underlying density, and b) are restricted to the locations of 
actual data points, which are unlikely to be in exactly the same position as the 
local pdf modes. Note that peaks can also arise, by random variation, even when 
there is no underlying local pdf mode. The essence of verification, discussed below, 
is to determine when peaks do reflect real underlying modes, or when they are 
merely chance occurrences. This random occurrence of peaks which do not reflect 
underlying modes can occur a) because of a chance grouping of data points, or b) 
because of an interaction between the estimated pdfs and the locations of the data 
points. We illustrate this last situation later in the chapter. 
One attractive property of Peaker is its computational efficiency in high-dimensional 
spaces which follows from restricting the search to the actual data points only. This 
avoids the potentially huge search required (for example, in scan statistics) when 
moving a window over a high-dimensional space. 
As a last note we would like to remark that Peaker does not serve the same 
function as a clustering tool. As mentioned, Peaker is well suited to detecting small 
local patterns^. Figure 7.1 shows one instance of a problem that cluster analysis 
would not be expected to perform well on, but Peaker is designed to detect. 
7.2 Densi ty Es t imat ion and Bandwid th Selection 
In section 7.1, we mentioned the use of kernel density estimation. In the paper by 
Adams et al. (2001), it was suggested that a simplified method could be used to 
^On the other hand, clustering is generally used to find overall partitions of the data and in 
most instances will search for large obvious clusters rather than small local patterns. 
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Figure 7.1: Example of a Small Local Peak 
obtain the pdf estimates. This was given by initially calculating 
= ^ E (7.1) 
y^nxix) 
for some nearest neighborhood size K, and setting f[x) as inversely proportional 
to g{x). This is akin to using a uniform kernel with K being the bandwidth. The 
reason cited for its use was the speed of computation. We feel that it would be more 
appropriate to use a more generahzed kernel as the penalty to computation is not 
severe (from the algorithmic outline in section 7.1, we can see that we do not store 
the distance ordering in step (1) and therefore would need to do an additional sort 
for the uniform kernel). 
Throughout the rest of the chapter we will assume the use of a multivariate 
n o 
Gaussian kernel, of the form 
j=i j=i •> 
where K{y) = exp{—\y'^). As we will see, this has certain advantages. Given the 
kernel function, we now need to choose appropriate values of the bandwidth h. There 
has been much literature on the selection of an optimal bandwidth, with different 
approaches given in Silverman (1986), Taylor (1989), Hall et al. (1991), Sheath k. 
Jones (1991), Wand & Jones (1994), Stone (1984) and Scott & Terrell (1987)^. Sain 
et al. (1994) gave multivariate extensions of these results. These methods are all 
based on minimizing data-driven approximations to the integrated squared error 
(ISE) and the mean integrated squared error (MISE), given by 
- - . f ( i r . s ) 
(7.4) 
jrd 
Of course, such data-driven optimization is computationally expensive and can 
sometimes give only local minima. Sain et al. (1994) showed that under the con-
straint ho = hi hd, one can obtain an exact expression for the minimizer 
of the asymptotic mean integrated squared error (AMISE). For instance, under the 
assumption of the data being generated from a single Gaussian jV(0, cri), we have 
ho = bypasses the optimization and we will make use of this result 
when appropriate. 
Of course, while it is desirable from a theoretical point of view to use the optimal 
bandwidth, we must never forget that Peaker is a practical tool and as such it may 
®For categorical data see Bowman (1980), Fienberg & Holland (1973), Brown & Rundell (1985) 
and Simonoff (1995). 
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be more appropriate in some cases to use a smaller bandwidth and thus better 
investigate local peaks, since the optimum bandwidth is a global optimum and it 
may be better to focus on detecting possible peaks. The Gaussian kernel also has 
the property that the number of modes is non-decreasing with increasing h. It may 
therefore be useful to vary the bandwidth. We will investigate this in a simulated 
study later. 
7.3 Identif icat ion of Significant Peaks 
This section describes the criteria by which we can detect peaks and the methods 
with which we can verify the significance of a peak once detected®. Moreover we 
should consider whether we are interested in detecting sharp peaks or peaks that 
occupy a large proportion of the density space (which we will refer to simply as large 
peaks). We can say that large peaks represent the more obvious structures within 
a data set, which would be picked up by standard modeling strategies, and that we 
are mainly concerned with only the small sharp peaks. 
All the above considerations (as well as the choices of distance metrics and 
density estimation) lead to different variants of the Peaker algorithm. As such, 
there is no single best algorithm which can answer all the questions posed. Peaker 
is an exploratory tool, and any of its different variants might be useful in detecting 
interesting and useful local structures. 
Before we move on, we must make an important distinction. Any data point can 
be one of the following: 
1. A mode (a maximum) - one which is a maximum in the density surface. To 
decide whether a point is a mode one needs to evaluate the entire density 
®To determine whether a detected peak represents a true anomaly of the underlying mechanism 
or whether it is a chance occurrence. 
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Figure 7.2: A Maximum 
surface around the point^. An example is shown in Figure 7.2. 
2. A maximum peak - a data point with higher pdf estimate than its nearest 
neighbours and which is also an approximation to a maximum. This is of 
course the essence of Peaker, since we only make use of density estimates at the 
data points and not the entire surface and so can only look for approximations. 
An example is shown in Figure 7.3. 
3. A non-maximum peak - This is simply a point which has a larger pdf esti-
mate than some neighbourhood of data points. Such a point does not need 
to approximate a maximum and arises due to a chance configuration of the 
neighbouring points (in one dimension, for instance, the nearest points with 
lower pdf estimates lying to one side of the peak). An example is shown in 
Figure 7.4. 
^In high-dimensional space this is very difficult. 
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Figure 7.3: A Maximum Peak 
Figure 7.4: A Non-Maximum Peak 
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4. A non-peak - A data point which has lower pdf estimate than its nearest 
neighbour. 
Intuitively one would like to detect maxima or approximations to maxima. This 
is rather difficult since it involves evaluation of the density surface. We will describe 
a method in the next section by which we can achieve this probabilistically. 
7.3.1 Setting M 
We have already mentioned the types of false peaks which can arise in the previous 
section. To make this more precise, we restrict our discussion to the univariate case®. 
Let a set of points ( z i , . . . be generated from some underlying probability 
density / , with cdf F. For any three consecutive points Xj-i,Xj,Xj+i, with true 
pdf f{xi^i) > f{xi) > f{xi+i), then Xi is a peak with M{xi) > 0 iff d{xi-i,xi) > 
d{xi,xi^i). In this instance Xi is a false peak since it is not a local maxima. We 
can say then that z, has some probability Pi of being a false peak where Pi = 
P{d{xi^i,xi) > d{xi,xi-^i)). Over the whole sample we can average over Pi to give 
an overall probability i?, which is the average probability that some point is a false 
peak. We can extend this further. For a set of consecutive points Zj_i, 2%,..., XiJ^ n^ 
with / ( z j - i ) > f{xi) > . . . > f(xi+rn), Xi IS a false peak with M{xi) = m and 
probability Rm = — R). This gives us a way of setting a value M initially 
such that we retain only the set of peaks Xi, M{xi) > m which are significant in the 
sense of being actual bumps in the data. 
We will now show that, as n —> oo, d({xi^i,xi) — d(xi,xi+i)) —> 0 by showing 
that E{d{xi^i,xi) — d(xi,xi+i)) —>• 0. To do this, we use order statistics and again 
assume the univariate case. 
Given a set of points (x i , . . . , Xn) generated from some probability density / with 
^Analogies to the multivariate case can also be made, but there are theoretical difficulties 
involved. 
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cdf F on %, the set of order statistics y i , . . . , is obtained by arranging the xs in 
ascending order on SR. The density function of the A:th order statistic, 1^, is given 
by 
^ (A - 1)^71 - V(3/k)(l - ^"(3/6))" - oo < < oo. (7.5) 
The joint density for Yfc and is given by 
n\ 
- o o < 3/t_i < !/& < oo. (7.6) 
fyk-uY,{yk-i,yk) = V(yfc-i)/(yfc)(i -i^(yfc))" 
We can then go on to obtain the density function for Dk = Ifc —^fc-i(2 < k < n), 
given by 
•n' 
/ D . ( 4 ) = ( f c _ 2 ) ! ( n - t ) ! J „ -f ( ^ ) ' ' V ( x ) / ( x + 4 ){1 - f ( 4 ) ) " - ' & , (7.7) 
0 < dk < oo. 
The joint density function for {Dk, -D/t+i) is given by 
f{x)f{x + dk)f{x + 4 + dk+i)dx, 
0 < dfc < CX3,0 < dfc+i < oo. 
Unfortunately, as one can see, none of the above expressions are simple for most 
/ . We can, however, use the following (Pyke (1965)); For 0 < u < u < 1, suppose 
s = F~^{u) and t = F''^{v) are uniquely defined, then if ^ > u and ^ ^ v 
lim = (1 - ea:p(-/(S)a:))(l - ea:p(-/(t)i/)). (7.9) 
116 
The density function for [Di, Dj) is then given by 
(<4, (7.10) 
0 < di < oo,0 < dj < oo. 
We can then obtain the density for Zi = Di — A - i , given by 
ea;p(n/(g)z(), < c((_i 
erp(-n/(g)zi), d; > (7.11) 
and Zi has expectation zero. 
Going back to the original problem, we can thus show that E{d{xi-i,xi) — 
d(xi, Xi+i)) = 0 as n —^  oo. 
There are three points we need to consider with the above. Firstly, we have 
assumed that we know the true underlying distribution of the data. This is of 
course not true in practice and we only have the kernel density estimates. But we feel 
justified in using the above as an approximation since we only require some ad hoc 
way of setting M, especially so since we will be using optimal bandwidth selection in 
the kernel estimation and can be reasonably confident of obtaining smooth estimates. 
Secondly we have shown the above for the case of univariate data only. The idea 
of order statistics in higher-dimensions is much more comphcated and there is no 
natural analogy of the univariate ordering. Barnett (1976) reviewed order statistics 
in multivariate data and the various proposed ideas of ordering, including M-ordering 
(marginal ordering) which orders the data in one of the dimensions and P-ordering 
(aggregate ordering) which derives a single value for each multivariate data point 
and orders the data accordingly. With these types of ordering it is not difficult to see 
that we can readily extend the ideas of this section. The last point is that we have 
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derived only a concrete method of setting M as n oo. We can try to empirically 
evaluate R, with one approximation being the ratio Rs = _ Here we have 
to be careful to eliminate the points which cannot be peaks^ from all data points. 
To do this we can simulate different sample sizes for some dimension and look for 
convergence towards some value Rg = r. This is the value at which the true R is 
from which we can derive the proportion of points which can never be peaks. 
Fortunately, we show below that, at reasonably low dimensions, we do not need a 
large number of data points for the limiting behavior to be true. 
Figure 7.5 shows that Rs converges to some value at dimension 1 to 5, for data 
size below 30,000 and is in fact close to the convergent value for much smaller sample 
sizes (around 10,000). Therefore we can reasonably assume R = \ unless for low 
sample sizes. 
7.3.2 Sharpness of a Peak 
Detecting peaks, as potential modes of the underlying pdf, is one thing, but we need 
to be reasonably confident that they are genuine, and not merely due to random 
fluctuation. We can explore this using ideas of significance tests, and of the proba-
bility mass of a peak. We now describe some methods of verifying the significance 
of detected peaks. 
A simple approach is to calculate the ratio of the pdf estimate at a peak to the 
average of the pdf estimates at the points in a surrounding neighbourhood. This is 
a measure of sharpness of the peak (which we call Tsharp)- The general form is given 
by 
Th - (712) 
where Ng is the number of nearest neighbours from which we take the average . For 
®In the univariate case the two end points are points which cannot be peaks. 
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Figure 7.5: Simulation Results for Convergence 
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simplicity we can set = y . Of course this is again rather arbitrary and moreover 
prone to distortion by specific arrangements of peaks. For instance, the sharpness 
of one peak can be very much affected by the shape of the neighbouring peaks (if a 
small sharp peak is close to a large flat peak, it is likely to have a smaller value of 
Tsharp)-
There are more sophisticated methods of measuring the sharpness of peaks. 
Bolton et al. (2004) described two such tests^°. The idea is to assume a null hy-
pothesis in which the points are locally uniformly distributed in a d-dimensional 
hyper-sphere of radius R. Denoting the distance of each point to the centre as X, 
then the transformed variate Y = is distributed as (7(0,1). The two tests are 
based on this transformed variate Y. 
The first test uses the test statistic 
1 " 
Zfepa,! = (7.13) 
where is the inverse of the cumulative normal distribution. Tieptoi is distributed 
as a N{0, ^) distribution. This test is based on the premise that a local dense region 
will have an abundance of short distances and a large negative value of Tieptoi-
The second test uses the r th order statistic Y(r) = and Y^ )^ follows a 
Beta{r, n — r + 1). Here Y j^.) will be smaller if there is a region of high density. 
7.3.3 Probability Mass Contained in Peaks 
An alternative to testing for the sharpness of a peak, is to derive a measure of the 
probability mass contained in a peak. This section follows the approaches contained 
in Silverman (1981), Good & Gaskins (1971), Good (1971) and Minnotte (1997), 
which are used to test for modes in the one-dimensional case. We assume the use of 
^°They refer to these tests as tests for leptokurtosis. 
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Gaussian kernel estimates^^. In Silverman (1981), to test the null hypothesis that 
the underlying density g has k modes, the test proposed uses the test statistic 
hcrit = inf(/i; f{x, h) has at most k-modes). (7.14) 
Here hcrit is the smallest value at which the data remains fc-modal. With the prop-
erty of the Gaussian kernel, one can perform a binary search to calculate hcrit- To 
obtain the significance level P{hcrit > ho), Silverman (1981) proposed sampling for 
g from the distribution g if g is known or sampling from a bootstrap density go 
obtained from the data if g is unknown. 
Minnotte (1997) extended the above to investigate each mode in turn. For a 
single mode Wj, he defined htest,i as the smallest h at which the mode remains a 
single mode, and proposed the test statistic 
Mi= f [f{x) ~max{f{ui-i)J{ui+i))]dx, (7.15) 
Jui-i 
where Ui^i and Ui+i are the two anti-modes either side of the mode In effect Mi 
is the area of probability mass above the higher of the two surrounding anti-modes. 
To obtain a p-value for Mi, the approach of Silverman (1981) is followed and points 
are sampled from a representative density of the region with no modes (possibly a 
uniform density). 
Higher-dimensional extensions to the above ideas are difficult to implement since 
it is computationally expensive to either a) look for anti-modes in high-dimensional 
space or b) obtain accurate significance levels by re-sampling. 
For our case, we simply calculate the ratio between an estimate of the density 
in the local region, and the density that this region would have if the local region is 
^^The Gaussian kernel has the property that the number of modes found in the data is non-
decreasing with decreasing bandwidth h, which facihtates the testing procedures. 
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part of a larger region in which, the density is uniform. Such a measure would have 
the generic form 
where f ixi) /Ns is an estimate of the density contained in the local region, 
defined as the region containing the nearest Ng points, and is an 
estimate of the density over the larger region, containing the nearest M points. 
There is, of course, some arbitrariness about the choices of M and Ng. 
7.3.4 Testing for Large Peaks 
We base our approach on that of Minnotte (1997). In our case, we do not calculate 
htest, since this is computationally expensive. Moreover, the use of htest is based on 
the desire to maximize the power of the test, since the use of the smallest band-
width minimizes the anti-modes and therefore maximizes the probability mass in 
the critical region. This is therefore a trade-off between power and computational 
complexity. We also require the anti-modes. This is quite difficult to find in high 
dimensions, particularly since we can not even make use of maximization. In this 
case, we make use of our version of the anti-mode, the anti-peak. An anti-peak 
is simply the opposite of a peak, so that Ui is an anti-peak with A(ui) = A iS 
f{ui) < f { u j ) y u j e Na{ui) but f{ui) > In keeping with the last sec-
tion, we define the nearest anti-peak to a peak as the closest anti-peak with some 
A{x) > a or the largest A(x) < a. However, in this case, we do not wish to obtain 
the p-value by resampling from a representative local distribution with no modes, 
which would be very expensive computationally. Instead we wish to obtain a more 
general statistic which would be monotonically increasing with decreasing p-value. 
In the approach of Minnotte (1997), the p-value is the percentage of s samples gen-
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erated from the local representative distribution which has more probability mass 
over the next higher anti-mode. Therefore it is clear that one obtains a low p-value 
if the probability mass constitutes a high proportion of all local probability mass. 
To test the significance of a peak Xi, we use the test statistic 
where A is the number of points to the nearest anti-peak and M the number of 
points to the next nearest neighbour with higher estimated pdf. T has to be scaled 
carefully with respect to the proportion of the sample space occupied by the A 
nearest neighbours and M nearest neighbours. 
7.3.5 Size of the Local Neighbourhood 
Much of the discussion in the previous sections is based on rather arbitrary selections 
of the neighbourhood size that we use to calculate various measures. This includes 
the neighbourhood size Ng used in Tsharp and Tdensity and the size of the uniform 
hyper-sphere used in the two tests by Bolton et al. (2004). The problem in all 
these cases is that these measures work well when the null model of local uniformity 
holds. For the various tests and ranking measures described so far, they only work 
well when the assumptions in the region of the test hold. When this is not the case, 
there are various ways for these measures to be distorted. For instance, if we have 
two identical peaks, one against a uniform background of higher pdf estimates than 
the other, then the measure Tgharp would return very different values for the two 
peaks. Similarly for the two tests contained in Bolton et al. (2004), it is imperative 
that the local hyper-sphere holds only one peak. In Minnotte (1997), such problems 
are resolved by only testing for uniformity of a mode in the local region bounded by 
the two nearest anti-modes. In our case, the neighbourhood M extends all the way 
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to the next peak. 
In the case of Peaker we cannot evaluate the anti-modes since we only work with 
the data points themselves. The most intuitive analogy to the anti-mode is the anti-
peak {i.e., a point which has a lower pdf estimate than its nearest points). We can 
make use of this in deciding on the neighbourhood sizes in that we can restrict any 
testing procedure to within the neighbourhoods bounded by the anti-peaks. Clearly 
there are also problems associated with this, since anti-peaks may be false and so 
make the neighbourhood sizes again rather arbitrary. Additionally, the meaning of 
a bounded region by anti-peaks is unclear, since there is no clear analogy to the 
high-dimensional case. In one dimension it is clear where the valleys on either side 
of a mode are, but in higher dimensions it is unclear which particular valleys we 
should extend the local region to. 
Having said this, we must not forget the exploratory nature of Peaker and as 
such it is important to experiment with differing neighbourhood sizes to look for 
otherwise undetected peaks. Therefore we are quite content in using rather arbi-
trary parameters in the Peaker algorithm knowing that one needs to explore these 
parameters to obtain peaks of different properties. 
7.4 Simulated S tudy 
The first example demonstrates the use of Peaker as a high-dimensional exploratory 
tool. The data set consists of 5000 data points in 10-dimensional space drawn from a 
mixture of background uniform and three Gaussian distributions. More data points 
in higher dimensional space can also be simulated. However, we simulate the above 
data set to reduce computational time while still giving a representative insight 
into the behaviour of Peaker. The Gaussian distributions have covariance matrices 
0.0251,0.0251,0.11 with mixing probabilities 0.0025,0.0025,0.02 respectively. The 
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background uniform is drawn in the hyper-box (—2, 2 ) , . . . , (—2, 2). For visuahzation 
we have reduced the data set down to two dimensions by plotting the points on the 
first two principal components. 
s l U H I i 
lapc 
Figure 7.6: First Two Principal Components of 10-dimensional Data With Three 
Modes 
The three Gaussian means are at (0,0), (2.32,0.81), (—2.32, —0.81) in Figure 7.6. 
The peak at (0.0) is detectable visuahy^^. It is not nearly as clear if we simply 
plot any two random dimensions, but the other two peaks are not at all clear by 
visualization (since the mixing probabilities are so low). It is interesting to note 
that here many peaks are thrown up for M = 200 say, but the three Gaussians are 
clearly detected when one uses the measure Tsharp (in that they give much higher 
values of Tsharp than other peaks). Of course Peaker is well designed for detecting 
^^However, this is distorted by the fact that we are plotting the first two principal components, 
which pushes the points towards the center. 
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such peaks otherwise undetectable by eye (since at high dimensions points are sparse 
and a small but dense region would be easily detected by Peaker). 
In the next example, we simulated from a mixture distribution of two indepen-
dent multivariate Gaussian distributions {MVNL, MVNS). We change the variables 
of the simulated data as follows; 
1. dimensionality, d = 2, 5. 
2. sample size, N = 1000, 5000. 
3. covariance matrix of MVN^, with mean at 0, ctl = 0.251, I. 
4. mixing probabilities for MVNs, Pmix — 0.025, p = 0.1. 
5. distance of the mean of MVNs to the mean of MVNL, dist = GL, 0.5(72,. 
For each combination of variables, 10 repeat samples are generated. 
To investigate the quality of the peaks obtained, we set M = 15, and the distance 
of each peak to the nearest true Gaussian mean (in the mixture distribution of two 
Gaussian distributions) is calculated. We then plot histograms of the peaks which 
fall under each distance interval. 
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Figure 7.7: Histograms of Peaks Corresponding to Distances From True Gaussian 
Means 
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Figure 7.8: Histograms of Peaks Corresponding to Distances From True Gaussian 
Means (Continued) 
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We can see from Figure 7.7 and Figure 7.8 that we obtain peaks closer to the 
true Gaussian means with larger N, smaller d, smaller larger Pmix and larger 
dist. These would be the expected results. If we look closer at the plots, we can 
make the following points: 
1. Dimensionality is clearly the most important factor in determining how close 
each detected peak is to the true mean. It is perhaps a surprise that sample size 
does not affect the performance of Peaker as much, but this can be explained by 
the fact that an increase in dimensionality makes the data points far sparser 
than a decrease in sample size. In higher dimensions the tendency is that 
the difference of the nearest neighbour to the furthest neighbour becomes 
smaller and more difficult to distinguish. In this regard it is not surprising 
that increasing the dimensionality makes the results worse. Moreover, it is 
often the case that the nearest data point approximating a true peak can be 
quite far away from the true peak. 
2. In terms of the two mixing probabilities, we can see that the performance of 
Peaker is quite similar. This suggests that Peaker is quite robust in detecting 
small local peaks with regards to the size and sharpness of the peak. This 
is a desirable feature of Peaker which sets it apart from other unsupervised 
pattern detection tools. 
3. In terms of the distance between the two Gaussian means, we can see quite 
clearly a significant decrease in performance as the two means become closer. 
At dist = O.dcxL, there is a large number of peaks at around distance 0.25 and 
1.1 from the true mean, which occurs when Peaker only detects one merged 
peak of the two true Gaussian means. However, this can be attributed more 
to the density estimation process than properties of Peaker. This effect can 
perhaps be reduced by using a smaller bandwidth. 
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4. Following on from the last point, the peaks at around distance 0.25 and 1.1 
from the true mean only occur for d = 5. This suggests that^Peaker can still 
detect distinct close peaks given a more densely populated space. Of course, 
this again is a property of the density estimation process since a large data set 
will give better estimates. 
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Chapter 8 
Anomaly Detection Under the 
New Approach 
We compare the signals obtained under a new^ approach to that obtained using the 
traditional methods^. Under the new approach, we use distance metrics obtained 
using the chemical properties of drugs and analytic properties of drugs and ADEs. 
We use Peaker to detect anomalously high concentrations of side effects under the 
effect of similarities among drugs. 
8.1 Detec t ing Groups of Similar Drugs 
We use a real data set to pick out interesting peaks amongst the drugs. The data 
set consists of 931 drugs. Chemical fingerprint data of the presence or absence of 
different molecular structures are available and the distance metric is the Jaccard 
coefficient. We run Peaker to detect dense regions of drugs which may have similar 
properties. We show the peaks obtained in reduced 2-dimensional space. 
We indicate various peaks in Figure 8.1 which represent some interesting pat-
^We will describe the new approach in this section. 
^Traditional methods denote the odds ratio, the GPS etc. 
131 
§ 
* , a n t i - d y s 
/ % p A r 
"r ««WM#( y * 
* * ' * t a * * 
* ' * » p . * 
* i * 
^ * * f A *» 
* %* . :f 
awi-itf 
P-peaktM=203 
Drug_group_name-paak(M=20) 
PCI 
Figure 8.1; First Two Principal Components Drugs Data Set Showing Peaks of 
the Common Drugs 
terns. All these peaks contain drugs almost exclusively of individual types. With 
a smooth bandwidth and iW = 20, we discover mostly peaks of the more common 
drugs (including anti-inflammatory, antineoplastic, anti-bacterial, anti-convulsant, 
anesthetic, anti-depressant and analgesic drugs) as shown in Figure 8.1. It is surpris-
ing that we have managed to find patterns of such purity (in terms of homogeneous 
drugs). 
Figure 8.2 shows the peaks found using a smaller bandwidth and M = 5. Some 
of the peaks found with M = 5 are not immediately obvious in similarity and it is 
only with further investigation that they are revealed as interestingly similar drugs. 
Certain drug peaks found have very low incidence rate in the data set (sometimes 
only 3 or 4 drugs). Overall there are not very many false peaks and most of the 
peaks found consist of interestingly similar groups of drugs, but this may be due 
to the closeness of chemical similarity to general behaviour of a drug. The general 
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Figure 8.2: First Two Principal Components Drugs Data Set Showing All Peaks 
trend seems to be that sharper peaks tend to show more homogeneous drug clusters. 
Indeed it does seem that Peaker can be applied to search for the rarer drugs that 
constitute interesting patterns or associations. 
8.2 Compar ison of Signals Using Simulated D a t a 
8.2.1 Simulation 
In this section we use a simulated example to compare the differences in signals 
obtained using the groups of similar drugs or ADEs. 
The data is simulated using a Multinomial background model for the drugs and 
ADEs. We simulate 300 drugs each with a profile of 200 ADEs. We add particular 
signals into the background Multinomial model and compare the tendencies of de-
tecting these signals. We keep track of all the artificial signals and detect them using 
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the Gamma-Poisson Shrinker and the new approach. The 300 drugs are separated 
groups of 10 each such that each group comprises of drugs of similar background 
Multinomial rates. Subsequently we can compare signals when there are inherent 
similarities among the drugs. We also insert 20 artificial signals at various points 
of the data set. Of course, this is a rather exaggerated situation when compared 
to real data, since in real data we would not have similar background Multinomial 
rates even when there are similarities in behaviour between drugs, but we can have 
a reasonable idea of the comparisons from this type of simulation. From section 8.1, 
we have seen that meaningful and interesting groups of drugs can be picked up using 
their chemical properties which constitute the real world data situation. Lastly, for 
the simulation we have deliberately made the drug profiles so that they are non-
sparse. We do this so that the distance metric used is no longer as important an 
issue which simplifies our task significantly. 
We first use GPS to analyse the signals. Here we only use a two parameter 
model to smooth the signals for the sake of simplicity. Table 8.1 shows the 20 
simulated signals and their strengths ordered by the GPS measure. We see that to 
a reasonable extent the signals are well picked up. The top signals comprise mostly 
of the true anomalies inserted. Moreover, keeping in mind that the inserted signals 
are themselves generated, so that some are not nearly as strong as others, we do see 
a good representative set of signals which are picked up by GPS. 
We run Peaker on the simulated drugs to look for drug groupings. We show the 
drugs plotted on the reduced 2-dimensional graph. We simply use the Euclidean 
distance between profiles of drugs and ADEs. The interesting point to note here 
is that most of the simulated drug signals are somewhat separated from the main 
clusters of drugs. This is to be expected since the simulated signals are different to 
the other drugs of the same simulated group. Indeed Peaker confirms this result. 
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Drug index Order of strength of signal 
31742 1 
234 2 
27124 3 
49109 6 
47801 7 
44699 8 
100 13 
16245 15 
37853 33 
51612 42 
55123 163 
38968 194 
41670 211 
53117 1195 
59144 1288 
1021 1485 
57138 1502 
43984 8147 
42771 10265 
28136 19510 
Table 8.1: Strength of Simulated Signals With GPS 
Here we simply use the quick method of estimating density (as described in chapter 
7) which estimates the density at each point as a weighted sum of the inverse of 
distances to the neighbouring points. Depending on the weights used in the density 
estimate, Peaker detects around 30 peaks with M < 9 and these comprise the 30 
groups of simulated drugs. It is interesting to note that none of the 20 simulated 
drug signals are at each one of these peaks, although some do appear at neighbouring 
points to these peaks. Indeed, the majority of the simulated drug signals only show 
as peaks with M = 1. 
The above analysis shows that a possible way to make use of the groups of drugs 
is to merge similar groups together. Since the simulated signals will be likely to be 
in individual groups by themselves, this should enable us to perform signal detection 
of the simulated signals against a background of merged drugs which can give us 
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better background rates and smooth out the random variation. To merge the drugs, 
we can potentially use Peaker, but this will lead to some overlap as well as having 
groups which can comprise of drugs which should not be in the group (without due 
care) since the drugs on the boundary of the neighbourhood of a peak may not 
necessarily belong to the same group as other drugs in the same neighbourhood. On 
the other hand, it is not ideal to use some clustering technique, since many of the 
signals are likely to be included in the large clusters if these signals are not strong 
enough. Indeed this is the case when K-nieans clustering is used. Here only 25 
clusters are produced and most of the simulated signals are incorporated into the 
larger clusters. 
We will perform two separate analyses using Peaker. In the first instance, we will 
use Peaker to pick out the groups of similar drugs, with due care to avoid overlap. 
We will restrict each group that constitutes a peak to the 7 drugs which are closest 
to the peak, thus avoiding some of the problem posed when disparate drugs are 
included in a group. This gives us 196 drugs into 28 distinct groups, we will treat 
the other drugs as individual groups. In fact, we have reduced our original 300 drugs 
into 132 groups and we hope that the combined drugs will give us better baselines. 
After grouping by Peaker, we see that, given our criteria of keeping only the 7 closest 
drugs to a peak in a group, in fact none of the simulated drug signals are included 
in the 28 groups. 
Table 8.2 shows the 20 simulated signals and their strengths ordered by the GPS 
measure after reduction of the drugs into groups by Peaker. Bearing in mind that the 
number of drugs has been reduced so that there are less signals overall, there is a vast 
improvement in terms of detection against all other background signals (although it 
is somewhat better in terms of ordering even given the reduced number of drugs). 
But the important point to keep in mind is that we have been able to vastly reduce 
the number of all background signals whilst still being able to detect the artificial 
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true signals in a somewhat better way (of course we would have expected this since 
none of the simulated signals are included in the large drug groups, as mentioned 
in the above paragraph). This in itself is enough to justify using the new approach 
since we have far less false positives to deal with. 
Drug index Order of strength of signal 
31742 1 
234 2 
27124 3 
49109 5 
47801 6 
44699 7 
100 9 
16245 10 
37853 20 
51612 24 
55123 53 
38968 68 
41670 88 
53117 392 
59144 439 
1021 519 
57138 528 
43984 1283 
42771 2247 
28136 5302 
Table 8.2: Strength of Simulated Signals After Reducing Size of Table With Peaker 
For the second analysis, we will include all drugs in groups as detected by Peaker 
and try to look for signals (using GPS) within each of the groups. Table 8.3 shows 
the 20 simulated signals and their strengths ordered within each group of drugs as 
picked up by Peaker. Here we see a dramatic change in terms of the strengths of 
the signals. Most of the simulated signals are now very well picked to the extent 
that 14 of them now occupy positions 1 or 2 in the within-group ordering. In a way, 
this is not as surprising as one may assume, since within each group the baseline 
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estimates are much better than can be obtained from all drugs. As such, it is much 
easier to pick up the true artificial signals. 
Drug index Order of strength of signal 
31742 2 
234 2 
27124 1 
49109 1 
47801 10 
44699 1 
100 8 
16245 1 
37853 1 
51612 108 
55123 52 
38968 5 
41670 1 
53117 1 
59144 1 
1021 1 
57138 1 
43984 22 
42771 2 
28136 1 
Table 8.3: Strength of Simulated Signals Within Each Group Picked by Peaker 
8.2.2 Discussion 
The simulated examples in section 8.2.1 show the value of making use of the simi-
larities among drugs and ADEs when attempting to detect signals. We have used 
Peaker initially to look for meaningful groups of drugs and subsequently performed 
analyses on the groups rather than the whole data set. We have seen that reduc-
ing the size of the overall data set by merging drugs within each group enables 
us to eradicate many false positive signals while not losing the true signals, whilst 
analysing each group individually enables us to much better detect the true signals. 
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A combination of these two approaches can also be utilised for potentially better 
combined results. 
Although the results do seem encouraging, it must be said that there are several 
points to consider. Firstly this simulation has been made to generate a non-sparse 
data set, which is contradictory to the real world scenario. With non-sparse data 
sets, it is much easier to employ meaningful distance metrics between profiles of 
drugs and ADEs and consequently to obtain meaningful groups. With sparse data 
sets, however, the choice of distance metric is critical and it is difficult to devise 
overall satisfactory metrics. Secondly we have simulated the data so that there 
are inherent similarities between drugs in terms of response to ADEs. This is by 
no means the case if we were to employ properties (such as chemical) in the real 
world scenario. However, it is to be hoped that such properties can be reasonable 
informative in terms of drug or ADE responses. 
Along with the distance matrices obtained analytically in chapter 5, we have 
other distance matrices obtained from chemical and biological information. It is 
therefore desirable to incorporate all the information into our distance. We can at-
tempt to combine these distances. With the distances obtained we can subsequently 
perform pattern search using Peaker. 
8.3 Combining Distances 
There are two separate cases in terms of combining distances; 
1. Given two distances obtained under two distance measures on the same vari-
ables. This situation arises when we have two distances {e.g., analytical and 
chemical) calculated between drug^ and drugs, and we need to calculate an 
overall distance. Given y[i]) and 2^(3^ (2], yp]) (where and xp] denote 
different attribute vectors measured on the variable x), the question is how we 
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can combine di and dg to obtain 
d{x,y\di,d2). 
One way is to combine the attribute vectors so that the distance is given by 
d{[x\i],xi2]]Ay[ihy[2]]). 
where [ccji],xp]] denotes a combined vector of X[i] and xp]. 
But in this case we have to use a single distance measure on the combined 
attribute vector, which may well not be appropriate. 
Alternatively we can put weights on the separate distances, such that 
d = adi + 0^2, 
and alter the weights a and (3 in the pattern search process to look for anoma-
lies under different weights. This approach, while in principle sensible, does 
put a lot of strain on the pattern search and requires careful interpretation of 
the anomalies found. 
2. The second issue concerns combining distances obtained under the same dis-
tance measure on different variables. This situation arises when we have dis-
tances between two drugs and between two ADEs, and we require a distance 
between two (drug, ADE) combinations. If we have d{xi,x2), (^ (2/1,3/2), we 
look for a combined distance 
4(3:1,3/1), (3=2,2/2)). 
This is in principle easier, since we can now simply combine the attribute 
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vectors. The only problem we need to take care with is the scaling of the 
combined vector so that we give equal weights to the two original vectors. 
8.4 Anomaly Detect ion 
We have three sets of distances on different variables that we can perform anomaly 
detection on. One between drugs, one between ADEs and one between combinations 
of drug and ADE. The next step is to use Peaker to detect anomalies in the data, 
with the final objective being to pick out unusually high counts of a (drug, ADE) 
combination. 
This particular approach to anomaly detection is based on three ideas: 
1. We do not want to assume independence in the contingency table as we would 
like to look for signals around a more localised setting, whereby we look for 
drugs which behave anomalously among similar drugs (similarly for ADEs and 
(drug, ADE) combinations). 
2. We minimize the effect of smoothing (with global smoothing parameters) and 
only base signals on localised behaviour. Of course, in analytically obtaining a 
distance matrix between drugs or ADEs, we have to use a degree of smoothing. 
Moreover, in applying Peaker, we have smoothing in the kernel-estimates. But 
these are very different from actually applying global smoothing parameters 
to any particular cell-count. In particular, we try to lessen the effect of having 
a few global smoothing parameters to smooth the measure of association and 
control for all the variation in the data. 
3. We take each drug and use the ADE counts to detect high anomalous counts 
at each drug. As a baseline at each drug we will use the smoothed counts 
estimated from the independence model. Aggregating the two counts will 
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show us the anomalously high side-effect regions. 
There are some problems associated with this approach. In the first instance, it 
may seem that to accurately detect anomalies, we need to obtain accurate distances 
in the first place. If we obtain only approximate distances, then it may seem the 
case that localised anomalies are meaningless. However, in terms of applying Peaker 
and thus calculating kernel estimates of a particular data point (in this case a drug 
for instance), we are only giving more weight to localised points around the data 
point. This, regardless of the degree of meaningfulness of the distance measure 
(assuming that the distances do actually have some significance and not completely 
unrelated to the proximity in behaviour of two drugs say), is surely better than 
assuming complete independence and thereby assigning equal weight to all points in 
the space. The second point is that without the smoothing of the cell estimates, we 
would detect anomalies which have small cell counts (akin to using the odds ratio). 
In this instance, we can use the same argument as before, which is that we need to 
look at all anomalies regardless of size and sharpness of the anomaly (indeed we can 
hope to detect the rare events better in this approach since we are detecting them 
in regions where they are more likely to occur). 
8.5 Example 
We provide an illustrative example using a real data set in the section. The data 
comes from a real data set provided by GlaxoSmithKline which contains 931 drugs 
crossed with 245 ADEs. Also provided with the contingency table is a set of chemical 
information comprising of the chemical fingerprints of the drugs. Jaccard coefficients 
are taken of the chemical information as a measure of the dissimilarities between 
the drugs and a distance matrix is provided. To illustrate our approach using the 
profiling method we analyse the data in the following steps: 
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• Using the chemical data, find all subsets of drugs which display some inherent 
similarities. Note that this example uses the same set of drugs as in section 
8.1 so that we can use the peaks that we have already detected in that section. 
• Using the profiling methods, find all subsets of drugs and ADEs which display 
some inherent similarities. We use the Bayes Factor only as the distance 
measure in this example and we look for instances whereby the groups are 
sensibly separated by some known similarities within the groups. 
• For each group of drugs, we take the ADEs as a set of counts from which we 
would look for peaks, taking into account the similarities between drugs. To 
do this, we look for high counts of ADEs for drugs that comprise each peak. 
A baseline for each such drug-ADE combination can be generated using the 
GPS and we compare this baseline with the ADE counts. In particular, we 
have the following three stage process: 
1. Given the groups of drugs detected using Peaker, use the ADEs as a 
profile for each drug. 
2. Compare the counts of the ADEs to the baseline obtained using the GPS. 
3. Look for anomalously high counts of ADEs such that within each group 
it is much higher than the baseline. 
Note that in the above approach it is not the case that we will end up with the 
drugs which provide high counts of ADEs as signals (drugs that produce nausea 
for instance). This is because drugs with high counts of a particular ADE will not 
necessarily constitute peaks, whereas we are specifically looking for high counts of 
a particular drug as compared to other drugs within the peaks detected. 
Table 8.4 to 8.6 show the signals we have generated using the approach outlined 
above. The odds ratio remains variable of course, this is reflected by the high 
143 
number of low counts that constitute the signals for the odds ratio. For the combined 
distance approach, shown in Table 8.6, we notice an interesting feature of the signals, 
which is that they are somewhat more stable than signals generated by the odds 
ratio but do not have such high counts as the smoothing method (GPS) produced 
in Table 8.5. In this sense we can say that these signals benefit from the smoothing 
being applied to neighbourhoods of similar drugs and ADEs. Moreover, we notice 
that some of the signals themselves derive from each other in the sense that they are 
neighbouring peaks within regions of similarities. In a wider sense, we can say that 
deriving signals in this way has allowed us to detect groups of signals and to be able 
to analyse these within the groups and between the groups. This is clearly a much 
more sensible way to calculate the signals than with an independence assumption. 
We now look more closely at Table 8.6. Note first of all that the column signal 
denotes the GPS baseline measure which is given to the drug-ADE combination. 
The drug-ADE combination itself is detected by running Peaker on each of the side-
effects against the drugs. We have merely given some of the more obvious peaks in 
Table 8.6 and there is no particular ordering in the table. We will go through the first 
few signals to give an idea of the peaks detected. The first signal comprises a high 
count in an anti-bacterial drug (as detected by Peaker in section 8.1). The signal is 
detected by comparing the count of the ADE with the baseline GPS of the ADE. 
We see that the GPS measure is by no means high compared to the highest GPS 
measures in Table 8.5. This is partly due to the fact that the signals are aggregated 
and partly due to the fact that the drugs have been grouped. The second signal in 
the table is one that comprises of the group anti-inflammatory drugs. Again here we 
note the GPS measure is very low. The third signal is that of anti-bacterial drugs 
again, but this time in a different peak to the first. 
More importantly, the new approach has allowed us to extract signals (combined 
or otherwise) which we were not able to before. In particular, the combined signals 
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in general are quite reflective of the behaviour that drugs in each group tend to 
exhibit individually. 
Drug index ADE index Count Odds Ratio 
13 156 3 10275 
475 54 1 10264 
115 44 1 (%31 
115 23 1 9221 
235 512 2 (#12 
532 23 2 8132 
251 143 1 8131 
545 232 3 8112 
565 113 2 8110 
567 62 2 8065 
123 15 3 8064 
877 34 2 7764 
231 54 4 in^7 
876 15 5 6446 
126 54 3 6245 
543 52 2 5544 
23 20 2 5043 
89 27 4 4634 
165 58 1 4233 
171 87 2 4133 
Table 8.4: Highest 20 Odds Ratios 
145 
Drug index ADE index Count GPS Signal 
263 226 32 201 
275 54 54 154 
165 72 23 151 
753 41 56 143 
841 12 223 141 
62 72 12 130 
2 17 11 123 
72 156 65 112 
74 113 42 112 
85 237 32 105 
73 164 13 103 
157 186 56 99 
853 219 12 96 
425 12 32 92 
523 19 8 91 
682 16 13 91 
25 202 56 89 
166 178 28 89 
245 18 16 88 
467 62 27 87 
Table 8.5: Highest 20 GPS Signals 
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Drug index ADE index Count GPS Signal 
163 192 29 35 
345 42 45 12 
62 92 8 72 
35 103 29 28 
247 104 95 51 
922 182 4 46 
36 52 67 24 
328 94 49 17 
467 62 27 87 
103 125 59 8 
57 204 29 48 
764 205 93 26 
92 20 190 34 
823 49 5 13 
62 72 12 130 
49 98 59 11 
204 184 20 52 
694 127 24 28 
195 18 75 29 
954 202 12 41 
Table 8.6: 20 Signals (Peaks) Detected Using New Approach (Using GPS as the 
Baseline Measure) 
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8.6 Conclusion 
In this chapter we have appHed the methods arrived at in the previous chapters 
to a set of real data. The main result shows that the new method is indeed able 
to derive different sets of signals to the older methods and that there is real scope 
to expand on this new approach. On the other hand, it is possible that the older 
methods can be employed alongside the new approach to achieve useful results. In 
a sense we are relying on the older methods to detect the actual signals, but within 
a more structured data set. This is superior in many ways and we have illustrated 
the new signals which we are able to detect. It also is a great help that we are able 
to use chemical information in this context since this greatly enhances the way that 
the profiling can be done. Bearing in mind the fact that it is very difficult to be 
able to profile appropriately using just the inherent drug and ADE counts, chemical 
properties is another way to be able to remedy this problem. 
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Chapter 9 
Conclusion and Future Research 
We have presented in this thesis the methods and ideas behind the important area 
of Pharmacovigilance. In this particular aspect, we have carried out analyses with 
regard to the detection and verification of anomalous signals which arise due to the 
adverse reactions that arise as a consequence of some drugs. It is imperative that 
such reactions can be detected quickly and effectively dealt with. Whether this can 
be achieved using the current methodology is a point of debate and we hope to have 
illustrated the many shortcomings that exist in the field today. 
In a sense, the remarks made in chapter 1 are particularly apt when considering 
the remainder of the thesis. We encounter the difficulties of data quality more than 
anything else in this area. When the data present difiiculties, it is sometimes rather 
pointless to delve into deep and sophisticated methods to solve such problems. The 
point is that one must first gain a thorough understanding of the data and the 
inherent behaviour before one can apply automated procedures. Perhaps this is 
precisely the reason why so many methods perform poorly and in practice are similar 
when used in this context (chapter 3 contains a detailed comparison so we will not 
explain further here). In defense of these methods, it might be said that nothing 
really can be achieved without the basis of using ratio measures as the central ideas 
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of such methods, since in most instances companies are interested in concrete results 
rather than a willingness to explore. 
Furthermore, we illustrate the alternatives which are possible. The central theme 
here is very simple, to utilise all information about the data before making a concrete 
decision on the type of analyses that we should perform. The extra information in 
our data comes in the shape of both chemical information and the inherent structures 
of the data. The idea is that, by using this information, we can establish the basis 
for measuring similarities among drugs and ADEs. These similarities will then 
further allow analyses based on the groups within the data. This is a significant 
improvement on the independence structure of the older models, which is severely 
restrictive on the types of analyses that can be performed. To obtain such similarties, 
we introduce the important concept of a suitable distance metric for sparse and high 
dimensional data. In particular we stress the importance attached to the ideas of 
distortive combinations of count data. Establishing that the Bayes Factor is a viable 
measure under such conditions, it becomes clear that this would allow us to establish 
a sensible and workable profiling system. 
To explore the data structures we have obtained, we introduce an important 
data exploratory tool called Peaker which helps to facilitate our analyses. Peaker 
is specifically designed to detect anomalously high concentrations of data points in 
high dimensional space. More to the point, it is designed to detect small localised 
regions of such high concentrations. In particular, Peaker only evaluates the density 
at each data point and in so doing bypasses the problem of high dimensions in which 
it would be extremely difficult to estimate the density surface. Being exploratory, 
however, also comes with difficulties when an accurate evaluation is needed in order 
to assess the significance of the detected peaks. In this regard we have introduced 
several methods of verification which can be applied. We emphasise exploratory 
here because that is precisely the philosophy we must take when applying Peaker. 
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We cannot expect everything to be answered by a simple press of a button, but 
rather we need to tweak the various parameters to obtain an in-depth knowledge of 
the structures within the data. 
9.1 D a t a Mining 
It has often been said that data mining is a discipline which by itself has no un-
derlying methodologies. This, however, in no way detracts from its importance as 
an area that contributes fully to the many facets of science. In Hand et al. (2001), 
data mining is described as the "search for anomalous local patterns within large 
databases, which are both interesting and useful to the user". The point is indeed 
to look for patterns which are of interest. This is a very apt description in the 
sense that within the real world environment, it is much more interesting and pro-
ductive to look for unexpected patterns rather than to partition the data in some 
way. Large partitions of the data generally reveal only obvious facts about the data 
which are well known already. On the other hand, it is precisely in the case of small 
local anomalies that one might discover interesting patterns that reveal insight into 
particular aspects of the data. Hand et al. (2001) furthermore gives the following 
representation of data 
data = structural part -f- patterns + random part. 
Note that this is in contrast to the otherwise held view in traditional statistics 
that only the structural and random parts are considered, or in classical language, 
structure and noise. We note that the addition of the patterns component has 
certainly changed the analysis somewhat since we would now be concerned with 
the detection and evaluation of these patterns as well as the structure and noise 
analysed in traditional statistics. Moreover the methods needed to analyse these 
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patterns need to be developed which can cope with the task of looking for patterns 
in often large and high dimensional data sets. This then, is perhaps one of the 
fundamental ideas of data mining, that of searching for patterns in large data sets. 
The methods developed in this thesis is one particular instrument in aid of searching 
for patterns, there are many more. In particular, methods such as that described in 
Friedman k. Fisher (1999) and various clustering procedures spring to mind. These 
methods are developed to combat the many issues arising from the data which have 
perhaps never been the focus of traditional statistical methods (which are generally 
concerned with statistical soundness rather than practical usefulness). Moreover, in 
the age of computer analysis, we are able to perform tasks on data sets which were 
not possible before. This in turn has led to a case of "if we are willing to explore 
then we can find some means to analyse even the very massive of data sets". 
The explosion in interest in data mining in recent years is a testament to the 
continuing growth of this area and the reliance many sectors now place upon such 
techniques. The underlying principle of most data mining tasks is the search for 
structures within large datasets. What sets this apart from many other more tra-
ditional techniques such as cluster analysis and classification is the interest in more 
localised structures which are otherwise difficult to detect when they are embed-
ded in huge datasets. This is applicable in various areas of society and is indeed 
one of the most sought after advances in statistics today, driven by the even ex-
panding databases which companies are now collecting. These applications include 
areas such as fraud detection (typically in large bank transaction databases), market 
analysis (an example would be customer behaviour in large supermarket transaction 
databases). Of course, another aspect of this wide-ranging capacity of data mining 
is the number of subject areas that it is applicable, including the physical sciences, 
the social sciences (such as phycology) and finance. The appreciation is that as data 
becomes more widely available it is also imperative to develop techniques which can 
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handle large quantities of data. Of course, with large datasets there is a tendency 
to develop methods which are rather ad hoc and perhaps do not possess the solid 
statistical foundations of the classical techniques. Indeed there is a general lack 
for unified methods and a formal approach to areas such as pattern discovery (in 
contrast to statistical modelling say) which is attributable to the area still being rel-
ative young and unexplored. This, however, is by no means disadvantageous if we 
can treat the problem with the right approach since any exploratory insight into the 
data can only be helpful towards the final goal. We have already mentioned one tool 
that we have developed in this thesis, which is called Peaker. The spirit of using this 
tool is precisely an exploratory approach. However, we hope to have demonstrated 
that one can fine-tune the many aspects of such a tool to obtain desired results. 
The particular aspect of data mining that we are concerned in this thesis is the 
area of pattern discovery, more specifically that of unsupervised pattern discovery. 
In Hand & Bolton (2004), unsupervised pattern discovery is described as "charac-
terizing and finding sets of values of the recorded variables which correspond to real 
features of the data generating process (they are not merely chance relationships) 
which are too small or local ... to form part of a model constructed to describe 
the data, and which are, in some sense, interesting or valuable". A pattern itself is 
defined as "a local structure that generates data with an anomalously high density 
compared with that expected under the (global) baseline model". Pattern discovery 
moreover is split into the two parts of pattern detection and pattern verification. In 
this thesis we have given examples of both in chapter 7. Pattern detection is the 
search for useful and interesting patterns while pattern verification is the testing 
thereafter carried out to ensure the veracity of the detected patterns. The detection 
of patterns usually involves searching for anomalously high regions of density in the 
data. In this sense anomalously high is relative to the baseline model. 
Alongside with data mining techniques there is also the important contribution 
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that software packages have made to the area of data mining. The general consensus 
is that today the computational power of most packages allows the user means to 
apply sophisticated techniques to large data sets, even without any particularly in-
depth knowledge about the tasks they are performing. We saw the power of such 
tools in chapter 6. In particular we illustrated the many facets to a data mining 
package that is required to compete in today's market. All these various aspects are 
crucial to the overall composition of a package. 
9.2 Summary of Thesis 
We made a case for the inefficiencies of many of the current methods being deployed 
in this area and suggested schematically ideas which could make improvements based 
on the use of inherent similarities among drugs and ADEs. At this point it would 
be as well to summarise the findings presented in the thesis so far and we will then 
discuss whether any improvements have been made. 
• In chapter 1 we present the background to the area of Pharmacovigilance and 
the ideas of signal detection within this area. We stress to the reader the scale 
of the problem associated with adverse reactions to drugs and discuss at length 
the various difficulties that can arise in the analysis phase due to the inherent 
data issues and political issues. As a result of some of these difiiculties we 
impress upon the reader the need for data mining techniques to be applied 
and the suitability of such techniques in this particular case. 
• Chapter 2 gives an in-depth summary of the data and issues concerning such 
data. In particular, we stress many of the deficiencies of the data in a sponta-
neous reporting database. This is even more valid for some databases which 
are less well organised than others. We then introduce an alternative type of 
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database which has not yet been properly explored for such analyses and give 
the advantages and disadvantages of utilising such a database. 
• Chapter 3 contains a review of the current state of technology in Pharmacovig-
ilance. In particular the methods presented here are utilised for the purposes 
of signal detection. We present and compare four different methods with il-
lustrative examples. In the final analysis we comment on the similarities of 
these methods in practice. The shortcomings of such methods are discussed 
and these as a whole are attributable to the general approach to the problem 
rather than any theoretical shortfalls. We introduce an idea by which we could 
hope to overcome such shortcomings. 
• Chapter 4 introduces the central theme of the thesis, which is an alternative 
approach based on the profiling approach. We describe the motivation behind 
the new approach as well as introduce the ideas and concepts in a generic 
sense. Also an outline for the remainder of the thesis is given. 
• Chapter 5 describes the profiling approach in detail. We also outline and 
discuss in depth the important concept of distance and the role it plays in 
our subsequent analyses. In particular we discuss the distances when under 
the conditions of sparse and high dimensional data. We compare the merits 
of four distance metrics under such conditions. Tied to all of this is of course 
the ideas of profiling and we illustrate using the distances metrics to compare 
the similarities of drugs and ADEs. The examples at the end of the chapter 
illustrate that the Bayes Factor would be likely to perform well with such data. 
• Chapter 6 is a rather stand-alone chapter separate from the rest of the thesis. 
It does, however, discuss one of the central issues in data mining today, namely 
the role of the software package. Here we use five packages to demonstrate 
the capabilities that software has evolved to this day. Comparisons are drawn 
155 
among the various packages as an illustration of the many advantages and 
disadvantages of designing a software package in a specific way. 
• Chapter 7 contains a tool called Peaker which is used to explore high di-
mensional data. Tied into the chapter we also introduce the ideas of pattern 
detection and verification. The underlying method to Peaker is fairly straight-
forward, however it is by no means simple to discover its properties. We 
introduce many ideas based on the verification of a peak once it has been de-
tected, which include both fairly ad hoc devices and more sophisticated tests. 
In particular, we impress upon the reader that as an exploratory tool it is best 
to utilise Peaker to its full capacity in order to achieve the best results. 
• In chapter 8 we utilise all the methods used in previous chapters in order to 
perform the anomalous signal detection using the alternative approach. We 
describe the way by which we combine the previously developed methods. We 
first look for simple groups within the drugs which reveal that many similar 
and moreover interesting groups can be detected. This further verifies the 
validity of taking such an approach. The final illustrative example shows the 
advantages of using the new approach. We are now able to perform many 
more types of analyses with the groups than the current methods. We can 
also illustrate by the signals that these are indeed better and more revealing 
than those detected with the older methods. 
9.3 Conclusion 
So what conclusions can we draw from the research carried out in this thesis? Prom 
a general point of view, we have advocated an approach of analysing Pharmacovig-
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ilance data^ which differs in principle to the older methods employed in this area. 
The main difference is that we dispense with the older approach that drugs and 
ADEs are independent entities and can only be analysed under the assumption of 
independence. Rather we attempt to look for structures that exist within the data 
and aim to use these structures to analyse the data in a more thorough way. The 
problem with taking such an approach, which has traditionally been considered im-
possible, is that it is rather difficult to obtain such structures due to both the poor 
quality of the data and the high dimensionality of the data. More concretely, we 
have mentioned the traditionally held view that drugs should not be grouped ac-
cording to their ADE profiles and vice versa. In a sense this is true, since this can 
be highly distorting to the final analysis. However, we have demonstrated that with 
the right approach and a willingness to explore, useful information can indeed be 
obtained from such data. In particular, we have illustrated that taking the new 
approach is certainly not disadvantageous in obtaining signals, but moreover can 
reveal aspects of the data which are not picked up by traditional methods. The 
signals detected are more stable when using the new approach and new signals are 
detected when analysing the groups both as a whole and within which would not be 
otherwise detectable under the older approaches. 
In chapter 8 we devised an alternative approach to detecting signals in Pharma-
covigilance data. In particular we used Peaker to look for signals within groups of 
drugs such that we can compare with the baseline signals generated by the GPS. 
The signals we generated showed that there is a substantial difference between the 
old and new signals. In particular, we have detected some signals which would not 
have been detectable under the older approach. In the main we have looked for 
signals which to some degree are aggregated between the peaks and the baseline. 
This has given us signals which are both robust and useful. The outline of such an 
^This is not restricted to Pharmacovigilance only, but is rather a general approach to many 
data mining tasks. 
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approach is that we first take the peaks found amongst the drugs and then match 
the ADEs to these drugs to discover the hidden possibilities. 
In the main we have derived an alternative approach to analysing signals. This 
is carried out in several steps, all of which are integral to the final analysis. Firstly 
we need to devise a sensible way of measuring similarities among drugs and ADEs. 
In more detail we need a suitable distance for this purpose. We show that the Bayes 
Factor is the most useful distance out of a selection of candidates. Using the Bayes 
Factor we can derive suitable similarities in high dimensional sparse data which 
is precisely the type of data that we are faced with. Secondly we need a useful 
way of exploring the similarities that we have derived. This is solved by using the 
Peaker algorithm which is designed to detect patterns in high dimensional space (in 
particular localised patterns). We utilise this to look for signals in groups of similar 
drugs and we have illustrated the results thereby arrived at. 
9.4 Fu tu re Work 
The three main areas of research that can be furthered are as follows: 
• Further research can be performed on the anomaly detection. In particular, 
further investigation into a suitable distance metric to utilise when comparing 
and combining drug and ADE profiles is desirable. This is by no means an 
easy task since intrinsically the data quality is a main obstacle in assessing the 
performance of such metric. We hope to explore this further in conjunction 
with any improvements that can be made possible in the quality of the data. 
• The data mining techniques that can be applied to detect anomalies can also 
be further investigated. We have introduced one tool for such purposes, but 
undoubtedly there are many other means through which we can identify sig-
nals. In particular, alternative methods to explore high dimensional spaces can 
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be applied which will perhaps reveal different insight into the data. Spatial 
modelling is another possibility, in which case it is probable that we would be 
able to obtain a more sophisticated representation of the data through which 
we would be able to utilise more complicated models. 
• Alternative databases can be explored alongside the SRDs. We have mentioned 
one such database (the GPRD) but have yet to be able to make good use of 
the type of data it holds. This is mainly because of the lack of insight into 
appropriate ways to make sense of such data. The GPRD is precisely opposite 
to the SRDs since it contains longitudinal data rather than the cross-sectional 
data contained in SRDs. Means to combining the two are particularly prob-
lematic since the GPRD is arguably of even poorer quality. The advantage, on 
the other hand, is the sheer volume of information that the GPRD contains 
and it would certainly be a major step forward if it becomes possible to utilise 
this information. 
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Appendix A 
Tables of Signals 
Results are generated using each of the methods OR, the Gamma-Poisson model, 
the Beta-Binomial model, the GPS and the BCPNN. The data used is a set of 172 
drugs and 2245 ADEs. The results are obtained by programs written in C. Detailed 
discussions of the results can be found in chapter 3. 
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Drug index ADE index Count Odds Ratio 
99 24 1 14137.9 
130 379 1 10603.4 
62 890 1 9896.5 
44 861 1 8996.82 
75 1075 2 8482.71 
26 542 1 8482.71 
26 1936 1 8482.71 
26 1705 1 8482.71 
53 1371 1 8247.08 
87 1090 2 7068.93 
78 644 1 7068.93 
111 648 1 5821.47 
31 469 2 5498.06 
97 1171 1 4948.25 
111 257 4 4657.18 
16 1802 1 4638.98 
16 1786 4 4638.98 
80 1261 1 4567.62 
59 1018 2 4498.41 
26 225 2 4241.36 
110 1249 9 4241.36 
18 1297 1 3906.51 
28 373 3 3806.35 
44 2180 2 3598.73 
147 161 1 3534.46 
61 258 2 3492.88 
77 1090 2 3298.83 
48 1927 1 3298.83 
21 926 1 3298.83 
153 588 1 3298.83 
13 1503 1 3298.83 
81 1670 2 3141.75 
83 855 3 3029.54 
44 2064 2 2998.94 
42 311 1 2939.55 
72 1552 1 2910.74 
34 294 2 2827.57 
26 939 1 2827.57 
27 352 3 2635.16 
17 1158 1 2604.34 
Table A . l : Highest 40 Odds Ratios 
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Drug index ADE index Count GPS signals 
158 2063 20 158.615 
135 2175 228 147.185 
144 2012 37 144.92 
169 1181 16 138.522 
135 317 158 136.952 
135 716 257 132.183 
135 707 57 124.293 
100 589 21 11&15 
42 95 12 112.125 
5 6 24 100.138 
93 1167 12 99.7102 
110 1249 9 99.3357 
139 560 9 97.7911 
110 180 9 93.6065 
5 809 19 91.7269 
135 360 190 91.1696 
169 1723 10 89.492 
125 1156 13 89.4524 
143 313 23 88.4922 
132 1338 28 87.416 
143 1822 11 87.3194 
143 358 25 86.6622 
122 421 11 84.3258 
92 2050 9 83.4615 
135 123 19 83.1669 
135 1376 21 82.6935 
132 621 24 82.1242 
39 1219 12 81.412 
93 1164 10 80.3663 
56 2050 9 79.0055 
140 1219 12 77.5629 
142 1340 9 76.4447 
102 1670 7 75.3204 
71 671 8 74.2088 
122 1368 11 72.8894 
171 1672 40 71.7762 
151 1155 38 71.7431 
151 1154 29 71.0506 
71 1265 10 69.8434 
56 371 7 67.6004 
Table A.2: Highest 40 GPS Signals 
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Drug index ADE index Count Gamma-Poisson measures 
99 24 1 13356.8 
130 379 1 10069.5 
62 890 1 8872.82 
75 1075 2 7849.48 
53 1371 1 7732.57 
44 861 1 7121.67 
26 542 1 6717.16 
26 1936 1 6717.16 
26 1705 1 6717.16 
78 644 1 6665.46 
87 1090 2 6531.22 
31 469 2 5035.71 
111 648 1 4618.5 
97 1171 1 4302.48 
16 1786 4 4225.42 
16 1802 1 4190.01 
111 257 4 4153.91 
59 1018 2 4005.55 
110 1249 9 3884.34 
26 225 2 3853.79 
18 1297 1 3779.65 
80 1261 1 3626.96 
28 373 3 3519.2 
147 161 1 3347.01 
44 2180 2 3319.15 
21 926 1 3301.52 
13 1503 1 3301.52 
48 1927 1 3227.68 
153 588 1 3136.35 
77 1090 2 3072.23 
81 1670 2 2968.64 
61 258 2 2959.98 
72 1552 1 2920.48 
44 2064 2 2794.71 
26 939 1 2681.62 
34 294 2 2635.97 
83 855 3 2632.01 
27 352 3 2463.09 
42 311 1 2336.88 
139 560 9 2302.72 
Table A.3: Highest 40 Gamma-Poisson Measures 
163 
Drug index ADE index Count Beta-Binomial measures 
99 24 1 14012.7 
130 379 1 10489 
62 890 1 9705.81 
44 861 1 8663.96 
75 1075 2 8429.46 
26 542 1 8169.04 
26 1936 1 8169.04 
26 1705 1 8169.04 
53 1371 1 8137.73 
87 1090 2 7020.41 
78 644 1 7018.85 
111 648 1 5606.76 
31 469 2 5473.37 
97 1171 1 4891.82 
111 257 4 4622 
16 1786 4 4616.53 
16 1802 1 4551.4 
59 1018 2 4472.07 
80 1261 1 4399.36 
110 1249 9 4235.27 
26 225 2 4200.92 
18 1297 1 3868.25 
28 373 3 3789.63 
44 2180 2 3571.13 
147 161 1 3489.46 
61 258 2 3427.66 
21 926 1 3285.26 
13 1503 1 3285.26 
48 1927 1 3283.34 
153 588 1 3278.65 
77 1090 2 3277.59 
81 1670 2 3127.64 
83 855 3 2991.79 
44 2064 2 2979.73 
72 1552 1 2899.63 
42 311 1 2831.45 
34 294 2 2809.51 
26 939 1 2791.79 
27 352 3 2627.02 
124 1076 1 2575.42 
Table A.4: Highest 40 Beta-Binomial Measures (Method of Moments) 
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Drug index ADE index Count BCPNN signals 
135 2175 228 92.8163 
135 716 257 9&123 
135 317 158 76.7478 
135 360 190 63.601 
171 276 121 44.981 
135 707 57 42.1396 
144 2012 37 32.4907 
117 645 396 31.4952 
171 1360 54 31.404 
117 1036 69 30.8728 
134 652 59 28.6499 
171 1672 40 27.7622 
171 1316 45 27.3953 
151 1155 38 26.8419 
171 1227 39 25.9428 
171 1485 78 25.7037 
155 761 99 25.59^ 
89 1273 66 25.1328 
170 340 35 24.8149 
5 8 195 24.4783 
68 1040 105 24.1953 
115 2185 34 24.1169 
115 643 39 23.7953 
115 1368 56 23.7201 
5 512 275 23.6285 
132 1338 28 23.5009 
151 1154 29 22.5322 
5 270 33 2&152 
143 358 25 21.6299 
5 6 24 21.6137 
90 1505 30 21.3815 
145 363 258 21.1906 
132 621 24 20.7302 
89 1563 45 20.4809 
143 313 23 20.454 
167 1506 42 20.2408 
158 2W63 20 20.2287 
89 276 84 20.1911 
100 589 21 20.1795 
171 87 82 19.8618 
Table A.5: Highest 40 BCPNN Signals (Uniform Prior) 
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Appendix B 
Cluster Analysis Results 
Figures are generated using single link and complete cluster analysis on each of the 
distances DuMouchel's method, Kullback-Liebler, and the Bayes Factor. The 
results are obtained by programs written in C. Detailed discussions of the results 
can be found in chapter 5. 
% 1 % 
Figure B . l : Cluster Analysis Plot of DuMouchel's Method (Single Linkage) 
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Figure B.2: Cluster Analysis Plot of DuMouchel's Method (Complete Linkage) 
Figure B.3: Cluster Analysis Plot of Kullback-Liebler Distance (Single Linkage) 
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Figure B.4: Cluster Analysis Plot of Kullback-Liebler Distance (Complete Linkage) 
W a r n 
Figure B.5: Cluster Analysis Plots of Distance (Single Linkage) 
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Figure B.6: Cluster Analysis Plots of Distance (Complete Linkage) 
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Figure B.7: Cluster Analysis Plots of Bayes Factor Distance (Single Linkage) 
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Figure B.8: Cluster Analysis Plots of Bayes Factor Distance (Complete Linkage) 
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